<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523417305147</prism:url><dc:identifier>doi:10.1016/j.ejmech.2017.06.060</dc:identifier><eid>1-s2.0-S0223523417305147</eid><prism:doi>10.1016/j.ejmech.2017.06.060</prism:doi><pii>S0223-5234(17)30514-7</pii><dc:title>Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>138</prism:volume><prism:startingPage>328</prism:startingpage><prism:endingPage>342</prism:endingpage><prism:pageRange>328-342</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2017-09-29</prism:coverdate><prism:coverDisplayDate>29 September 2017</prism:coverdisplaydate><prism:copyright>© 2017 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Salado, Irene G.</dc:creator><dc:creator>Zaldivar-Diez, Josefa</dc:creator><dc:creator>Sebastián-Pérez, Víctor</dc:creator><dc:creator>Li, Lingling</dc:creator><dc:creator>Geiger, Larissa</dc:creator><dc:creator>González, Silvia</dc:creator><dc:creator>Campillo, Nuria E.</dc:creator><dc:creator>Gil, Carmen</dc:creator><dc:creator>Morales, Aixa V.</dc:creator><dc:creator>Perez, Daniel I.</dc:creator><dc:creator>Martinez, Ana</dc:creator><dc:description>
                  Leucine-rich repeat kinase 2 (LRRK2) is one of the most pursued targets for Parkinson's disease (PD) therapy. Moreover, it has recently described its role in regulating Wnt signaling and thus, it may be involved in adult neurogenesis. This new hypothesis could give rise to double disease-modifying agents firstly by the benefits of inhibiting LRRK2 and secondly by promoting adult neurogenesis. Herein we report, the design, synthesis, biological evaluation, SAR and potential binding mode of indoline-like LRRK2 inhibitors and their preliminary neurogenic effect in neural precursor cells isolated from adult mice ventricular-subventricular zone. These results open new therapeutic horizons for the use of LRRK2 inhibitors as neuroregenerative agents. Moreover, the indolinone derivatives here prepared, inhibitors of the kinase activity of LRRK2, may be considered as pharmacological probes to study the potential neuroregeneration of the damaged brain.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>LRRK2 inhibitors</dcterms:subject><dcterms:subject>Protein kinase inhibitors</dcterms:subject><dcterms:subject>Indolinone</dcterms:subject><dcterms:subject>Adult neurogenesis</dcterms:subject><dcterms:subject>Neural stem cell</dcterms:subject><dcterms:subject>Regenerative medicine</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523417305147" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523417305147" rel="scidir"/></link></coredata><objects><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="8394">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="130" size="17845">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="11514">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="86" size="10164">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="116" size="12370">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="128" height="163" size="25384">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="33718">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="164" size="21674">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="87" size="16801">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="190" height="164" size="10771">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="511" height="245" size="32782">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="336" height="200" size="39709">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="324" size="55081">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="534" height="210" size="45701">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="330" size="57724">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="313" height="399" size="88401">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="383" size="80957">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="451" size="74950">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="758" height="299" size="107179">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="111" height="96" size="20376">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2264" height="1087" size="157695">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1488" height="886" size="211055">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="1434" size="328578">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2366" height="929" size="217039">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1462" size="330487">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1386" height="1769" size="569898">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="1696" size="536488">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2665" height="1997" size="502047">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3354" height="1325" size="678647">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="492" height="425" size="40035">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="2256704">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417305147-mmc1.docx?httpAccept=%2A%2F%2A</object></objects><scopus-id>85021776951</scopus-id><scopus-eid>2-s2.0-85021776951</scopus-eid><pubmed-id>28688273</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85021776951" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20170629">2017-06-29</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20170629">2017-06-29</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20170705">2017-07-05</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20170705">2017-07-05</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2017-08-29T10:02:11</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523417305147</xocs:eid>
      <xocs:pii-formatted>S0223-5234(17)30514-7</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523417305147</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2017.06.060</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523417X00123</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20170830">2017-08-30T06:59:46.725252-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20170929</xocs:date-search-begin>
      <xocs:year-nav>2017</xocs:year-nav>
      <xocs:indexeddate epoch="1498719834">2017-06-29T07:03:54.246562Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>138</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>138</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 138</xocs:vol-iss-suppl-text>
      <xocs:sort-order>32</xocs:sort-order>
      <xocs:first-fp>328</xocs:first-fp>
      <xocs:last-lp>342</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>328</xocs:first-page>
         <xocs:last-page>342</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20170929</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>29 September 2017</xocs:cover-date-text>
      <xocs:cover-date-start>2017-09-29</xocs:cover-date-start>
      <xocs:cover-date-year>2017</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2017 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>LEUCINERICHREPEATKINASE2LRRK2INHIBITORSBASEDINDOLINONESCAFFOLDPOTENTIALPRONEUROGENICAGENTS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>SALADO</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>I</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Design of new compounds</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Kinase inhibition activity evaluation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Structure-activity relationships and molecular modeling studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Prediction of blood brain barrier (BBB) permeability</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Neurogenic properties of LRRK2 inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular modelling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>ZIMPRICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>601</xocs:ref-first-fp>
            <xocs:ref-last-lp>607</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>HEALY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>583</xocs:ref-first-fp>
            <xocs:ref-last-lp>590</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>GILLIGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>927</xocs:ref-first-fp>
            <xocs:ref-last-lp>938</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>ESTRADA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6733</xocs:ref-first-fp>
            <xocs:ref-last-lp>6746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>COOKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>42</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>STEGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>47</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>BERWICK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>82</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>ABDIPRANOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>187</xocs:ref-first-fp>
            <xocs:ref-last-lp>210</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>LAMM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2817</xocs:ref-first-fp>
            <xocs:ref-last-lp>2830</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>HIROTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>222</xocs:ref-first-fp>
            <xocs:ref-last-lp>230</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>WETZEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>10800</xocs:ref-first-fp>
            <xocs:ref-last-lp>10826</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>WILK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>491</xocs:ref-first-fp>
            <xocs:ref-last-lp>497</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>MEDVEDEV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>151</xocs:ref-first-fp>
            <xocs:ref-last-lp>162</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>KAUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>858</xocs:ref-first-fp>
            <xocs:ref-last-lp>894</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>IKOTUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>416</xocs:ref-first-fp>
            <xocs:ref-last-lp>422</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>PANDEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>49</xocs:ref-first-fp>
            <xocs:ref-last-lp>53</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>KAUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>991</xocs:ref-first-fp>
            <xocs:ref-last-lp>1015</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>OTTONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>13915</xocs:ref-first-fp>
            <xocs:ref-last-lp>13928</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>CORREIAGUEDES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>237</xocs:ref-first-fp>
            <xocs:ref-last-lp>242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>WEST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>16842</xocs:ref-first-fp>
            <xocs:ref-last-lp>16847</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1725</xocs:ref-first-fp>
            <xocs:ref-last-lp>1736</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>HASSANEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>543</xocs:ref-first-fp>
            <xocs:ref-last-lp>549</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>5536</xocs:ref-first-fp>
            <xocs:ref-last-lp>5545</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>DI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>223</xocs:ref-first-fp>
            <xocs:ref-last-lp>232</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>CRIVORI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2204</xocs:ref-first-fp>
            <xocs:ref-last-lp>2216</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>ERNST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1072</xocs:ref-first-fp>
            <xocs:ref-last-lp>1083</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>GILPEROTIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1435</xocs:ref-first-fp>
            <xocs:ref-last-lp>1452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>HERRERAAROZAMENA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>KRIZA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>696</xocs:ref-first-fp>
            <xocs:ref-last-lp>701</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>VINE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>931</xocs:ref-first-fp>
            <xocs:ref-last-lp>938</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>KOUZNETSOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5855</xocs:ref-first-fp>
            <xocs:ref-last-lp>5857</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>DANDIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>201</xocs:ref-first-fp>
            <xocs:ref-last-lp>205</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>KHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>243</xocs:ref-first-fp>
            <xocs:ref-last-lp>249</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>342</xocs:ref-first-fp>
            <xocs:ref-last-lp>351</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>BARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>217</xocs:ref-first-fp>
            <xocs:ref-last-lp>222</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>SEKULARAC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1347</xocs:ref-first-fp>
            <xocs:ref-last-lp>1354</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>MCGOOKIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1955</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>66</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>AZIZIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>9721</xocs:ref-first-fp>
            <xocs:ref-last-lp>9723</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>POPP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1984</xocs:ref-pub-year>
            <xocs:ref-first-fp>1641</xocs:ref-first-fp>
            <xocs:ref-last-lp>1645</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>ALKAHRAMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>491</xocs:ref-first-fp>
            <xocs:ref-last-lp>495</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9198</xocs:ref-first-fp>
            <xocs:ref-last-lp>9203</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>BIANCHINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>412</xocs:ref-first-fp>
            <xocs:ref-last-lp>422</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-first-fp>272</xocs:ref-first-fp>
            <xocs:ref-last-lp>274</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>CORSICOCODA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1987</xocs:ref-pub-year>
            <xocs:ref-first-fp>2843</xocs:ref-first-fp>
            <xocs:ref-last-lp>2852</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>SAREL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1964</xocs:ref-pub-year>
            <xocs:ref-first-fp>143</xocs:ref-first-fp>
            <xocs:ref-last-lp>150</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>6853</xocs:ref-first-fp>
            <xocs:ref-last-lp>6860</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>BAIROCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>55</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>THOMPSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>4673</xocs:ref-first-fp>
            <xocs:ref-last-lp>4680</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>GUEX</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>2714</xocs:ref-first-fp>
            <xocs:ref-last-lp>2723</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>GHOSE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-first-fp>1050</xocs:ref-first-fp>
            <xocs:ref-last-lp>1065</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>GOPALAKRISHNAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>669</xocs:ref-first-fp>
            <xocs:ref-last-lp>671</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>EISENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>396</xocs:ref-first-fp>
            <xocs:ref-last-lp>404</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>NIETOESTEVEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2194</xocs:ref-first-fp>
            <xocs:ref-last-lp>2209</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>SALADOX2017X328</xocs:refkey3>
         <xocs:refkey4lp>SALADOX2017X328X342</xocs:refkey4lp>
         <xocs:refkey4ai>SALADOX2017X328XI</xocs:refkey4ai>
         <xocs:refkey5>SALADOX2017X328X342XI</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:self-archiving>
         <xocs:sa-start-date>2019-07-05T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-embargo-status>UnderEmbargo</xocs:sa-embargo-status>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2017 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(17)30514-7</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523417305147</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523417305147</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2017.06.060</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2017-08-30T06:59:46.725252-04:00</xocs:timestamp>
         <xocs:cover-date-start>2017-09-29</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/MAIN/application/pdf/85ff1f1d9b71f74bf78d56be0a8d0f2e/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/MAIN/application/pdf/85ff1f1d9b71f74bf78d56be0a8d0f2e/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1746020</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>15</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523417305147-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/PREVIEW/image/png/3f8dcfa5a96db9c744cffd7384ea7686/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/PREVIEW/image/png/3f8dcfa5a96db9c744cffd7384ea7686/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>56394</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/sc1/THUMBNAIL/image/gif/13a3b511a658bd57476a6abc6162d55e/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/sc1/THUMBNAIL/image/gif/13a3b511a658bd57476a6abc6162d55e/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8394</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/fx1/THUMBNAIL/image/gif/e646a753e23e67aafe8d942f01a89913/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/fx1/THUMBNAIL/image/gif/e646a753e23e67aafe8d942f01a89913/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17845</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr1/THUMBNAIL/image/gif/401f9bd9667d3b1ef2a31be5c1ff6018/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr1/THUMBNAIL/image/gif/401f9bd9667d3b1ef2a31be5c1ff6018/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11514</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr2/THUMBNAIL/image/gif/41af0608aad58d863ec4db98274eeb04/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr2/THUMBNAIL/image/gif/41af0608aad58d863ec4db98274eeb04/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10164</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr3/THUMBNAIL/image/gif/42f615861300b99b7a91f468aea938ad/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr3/THUMBNAIL/image/gif/42f615861300b99b7a91f468aea938ad/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12370</xocs:filesize>
               <xocs:pixel-height>116</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr5/THUMBNAIL/image/gif/389aecfff481c7c51ec6c38e72aab883/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr5/THUMBNAIL/image/gif/389aecfff481c7c51ec6c38e72aab883/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>25384</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr6/THUMBNAIL/image/gif/ae84a8543895362e851d7471fdf46b70/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr6/THUMBNAIL/image/gif/ae84a8543895362e851d7471fdf46b70/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>33718</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr7/THUMBNAIL/image/gif/0beb590fa8a2a10b4db1e1560f03f4c8/gr7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr7/THUMBNAIL/image/gif/0beb590fa8a2a10b4db1e1560f03f4c8/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>21674</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr4/THUMBNAIL/image/gif/096b2694bdd9d5ae8e1bca6cd5a43bd9/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr4/THUMBNAIL/image/gif/096b2694bdd9d5ae8e1bca6cd5a43bd9/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16801</xocs:filesize>
               <xocs:pixel-height>87</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/fx2/THUMBNAIL/image/gif/45901f758e444f877761ee846eb81232/fx2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/fx2/THUMBNAIL/image/gif/45901f758e444f877761ee846eb81232/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10771</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>190</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/sc1/DOWNSAMPLED/image/jpeg/227ad32ce1adbec820523a12fef01d46/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/sc1/DOWNSAMPLED/image/jpeg/227ad32ce1adbec820523a12fef01d46/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32782</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>511</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/fx1/DOWNSAMPLED/image/jpeg/38565c0abc6e4b7266b8b2e9a944bf4f/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/fx1/DOWNSAMPLED/image/jpeg/38565c0abc6e4b7266b8b2e9a944bf4f/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39709</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>336</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr1/DOWNSAMPLED/image/jpeg/30b76d6f4c4e1fe39ad002907ca3450a/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr1/DOWNSAMPLED/image/jpeg/30b76d6f4c4e1fe39ad002907ca3450a/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>55081</xocs:filesize>
               <xocs:pixel-height>324</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr2/DOWNSAMPLED/image/jpeg/f083b5ef09f2bb13829f0efc5146fa0a/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr2/DOWNSAMPLED/image/jpeg/f083b5ef09f2bb13829f0efc5146fa0a/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45701</xocs:filesize>
               <xocs:pixel-height>210</xocs:pixel-height>
               <xocs:pixel-width>534</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr3/DOWNSAMPLED/image/jpeg/975394c6feb6a615594a430d526e246a/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr3/DOWNSAMPLED/image/jpeg/975394c6feb6a615594a430d526e246a/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>57724</xocs:filesize>
               <xocs:pixel-height>330</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr5/DOWNSAMPLED/image/jpeg/dcfa3615ae8ac1cdea579b52e6a5a17c/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr5/DOWNSAMPLED/image/jpeg/dcfa3615ae8ac1cdea579b52e6a5a17c/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>88401</xocs:filesize>
               <xocs:pixel-height>399</xocs:pixel-height>
               <xocs:pixel-width>313</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr6/DOWNSAMPLED/image/jpeg/1e035fac3bf10e70f6eb73f0736875bb/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr6/DOWNSAMPLED/image/jpeg/1e035fac3bf10e70f6eb73f0736875bb/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>80957</xocs:filesize>
               <xocs:pixel-height>383</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr7/DOWNSAMPLED/image/jpeg/85f6dfa44bf3e8dc937a1beda7067987/gr7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr7/DOWNSAMPLED/image/jpeg/85f6dfa44bf3e8dc937a1beda7067987/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>74950</xocs:filesize>
               <xocs:pixel-height>451</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr4/DOWNSAMPLED/image/jpeg/9b0debe489c42178d78fd493f9673eda/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr4/DOWNSAMPLED/image/jpeg/9b0debe489c42178d78fd493f9673eda/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107179</xocs:filesize>
               <xocs:pixel-height>299</xocs:pixel-height>
               <xocs:pixel-width>758</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/fx2/DOWNSAMPLED/image/jpeg/095afe9409a9f3d272362d81103644c0/fx2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/fx2/DOWNSAMPLED/image/jpeg/095afe9409a9f3d272362d81103644c0/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20376</xocs:filesize>
               <xocs:pixel-height>96</xocs:pixel-height>
               <xocs:pixel-width>111</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/sc1/HIGHRES/image/jpeg/8e7730d9ae82093ac0524869cb285ca1/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/sc1/HIGHRES/image/jpeg/8e7730d9ae82093ac0524869cb285ca1/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>157695</xocs:filesize>
               <xocs:pixel-height>1087</xocs:pixel-height>
               <xocs:pixel-width>2264</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/fx1/HIGHRES/image/jpeg/b0a460d64ae5112744dfcc82ee845223/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/fx1/HIGHRES/image/jpeg/b0a460d64ae5112744dfcc82ee845223/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>211055</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1488</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr1/HIGHRES/image/jpeg/e8a77179d102f6b31dd35411876a2314/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr1/HIGHRES/image/jpeg/e8a77179d102f6b31dd35411876a2314/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>328578</xocs:filesize>
               <xocs:pixel-height>1434</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr2/HIGHRES/image/jpeg/10cfdda5922d32278a55879df7a1dddc/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr2/HIGHRES/image/jpeg/10cfdda5922d32278a55879df7a1dddc/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>217039</xocs:filesize>
               <xocs:pixel-height>929</xocs:pixel-height>
               <xocs:pixel-width>2366</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr3/HIGHRES/image/jpeg/f296e58696754a150e2629df37e66a53/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr3/HIGHRES/image/jpeg/f296e58696754a150e2629df37e66a53/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>330487</xocs:filesize>
               <xocs:pixel-height>1462</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr5/HIGHRES/image/jpeg/c1b1aa62bb47b5285d9e96fbca38714d/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr5/HIGHRES/image/jpeg/c1b1aa62bb47b5285d9e96fbca38714d/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>569898</xocs:filesize>
               <xocs:pixel-height>1769</xocs:pixel-height>
               <xocs:pixel-width>1386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr6/HIGHRES/image/jpeg/a71fc97aff9a61351dc685ff9a2f735a/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr6/HIGHRES/image/jpeg/a71fc97aff9a61351dc685ff9a2f735a/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>536488</xocs:filesize>
               <xocs:pixel-height>1696</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr7/HIGHRES/image/jpeg/2c4d842af24fe399587d01afe875e902/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr7/HIGHRES/image/jpeg/2c4d842af24fe399587d01afe875e902/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>502047</xocs:filesize>
               <xocs:pixel-height>1997</xocs:pixel-height>
               <xocs:pixel-width>2665</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/gr4/HIGHRES/image/jpeg/90d8c9376babf7395cd95653d41001dc/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/gr4/HIGHRES/image/jpeg/90d8c9376babf7395cd95653d41001dc/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>678647</xocs:filesize>
               <xocs:pixel-height>1325</xocs:pixel-height>
               <xocs:pixel-width>3354</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/fx2/HIGHRES/image/jpeg/042bc84c8c3be3a74026af346a099883/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/fx2/HIGHRES/image/jpeg/042bc84c8c3be3a74026af346a099883/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40035</xocs:filesize>
               <xocs:pixel-height>425</xocs:pixel-height>
               <xocs:pixel-width>492</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417305147-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417305147/mmc1/MAIN/application/msword/a446303fe31b3be41b2f44201cf8cff0/mmc1.docx</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417305147/mmc1/MAIN/application/msword/a446303fe31b3be41b2f44201cf8cff0/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>2256704</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.4" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>9555</aid>
            <ce:pii>S0223-5234(17)30514-7</ce:pii>
            <ce:doi>10.1016/j.ejmech.2017.06.060</ce:doi>
            <ce:copyright type="full-transfer" year="2017">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Structure of known protein kinase inhibitors with indolinone scaffold.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0015">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Designed compounds following a biology-oriented synthesis (BIOS) approach and consideration of the indolinone ring as a privileged scaffold.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Different <ce:italic>E:Z</ce:italic> isomers of the indolinone imino and hydrazone derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Kinase profiling of indolinone <ce:bold>16</ce:bold> (light blue) and <ce:bold>38</ce:bold> (dark blue) at compound fixed concentration of 10 μM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">A) Binding mode of indolinone <ce:bold>33</ce:bold> into catalytic site of LRRK2. B) Superposition of compounds <ce:bold>33</ce:bold> (blue color) and <ce:bold>39</ce:bold> bound to LRRK2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Indolinones <ce:bold>33</ce:bold> and <ce:bold>39</ce:bold> bound to LRRK2. Green and orange arrows show the two back cavities present in the active site of LRRK2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Effects of LRRK2 inhibitors on neurosphere formation. (A–B) Representative bright field micrographs showing the size of primary neurospheres after 3 days in culture in the presence of DMSO as a control (A) or LRRK2 inhibitor <ce:bold>38</ce:bold> (B). (C–D) Quantitative analysis of the neurospheres in culture. The total neurosphere area was measured (C) and the number of neurospheres was counted (D) in each field using an especially designed macro for IMAGE J. Results are mean value ± SEM, represented as relatives to control value (=100), of five different fields each one from triplicates and from three independent experiments. Bar in A: 100 μm *p ≤ 0.05; **p ≤ 0.005.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Reaction conditions: i) MMT-K10, MW, 10–100 °C, 5–30 min; ii) EtOH, KOH, SO<ce:inf loc="post">4</ce:inf>Me<ce:inf loc="post">2</ce:inf> or BrBn; iii) DMF, NaH, CH<ce:inf loc="post">3</ce:inf>I or BrBn; iv) MW, 110 °C, 0.5–1.5 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/sc1"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="bottom" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="tspara0010" view="all">Reaction yields, <ce:italic>E:Z</ce:italic> isomeric ratios, predicted blood-brain barrier (BBB) penetration and biological activity (LRRK2 inhibition and Wnt signal enhancement) of synthetized isatines <ce:bold>1–50</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Table 1</ce:alt-text>
               <tgroup cols="11">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <colspec colnum="7" colname="col7"/></colspec>
                  <colspec colnum="8" colname="col8"/></colspec>
                  <colspec colnum="9" colname="col9"/></colspec>
                  <colspec colnum="10" colname="col10"/></colspec>
                  <colspec colnum="11" colname="col11"/></colspec>
                  <thead>
                     <row valign="top" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col1" nameend="col11" align="center">
                           <inline-figure baseline="0.0">
                              <link locator="fx2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/fx2"/></link>
                              <alt-text role="short" id="alttext0055">Image 2</alt-text>
                           </inline-figure>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Comp. No.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<sup loc="post">1</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<sup loc="post">2</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Yield</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>E:Z</italic> ratio</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">LRRK2 %inh@10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">LRRK2 IC<inf loc="post">50</inf> (μM)<cross-ref refid="tbl1fna" id="crosref0585">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">LRRK2 G2019S %inh @10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">LRRK2 G2019S IC<inf loc="post">50</inf> (μM)<cross-ref refid="tbl1fna" id="crosref0590">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">BBB</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-NO<inf loc="post">2</inf>-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">50%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">63:37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">19%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-OMe-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">75%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83:17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">63%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">75%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-Br-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">84%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">77:23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">11%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">86%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83:17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">71%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">70%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.98</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-OMe-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">27%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83:17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-CF<inf loc="post">3</inf>-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">53%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">62:38</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">12%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-Cl-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">77:23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-F-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">60%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">67:33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">60%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">73%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-Cl-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">10%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">63:37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">39%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-F-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">71%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">67:33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">71%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">69%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CN-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">56%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">64:36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">45%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-NO<inf loc="post">2</inf>-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">24%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">64:36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">66%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-N(Me)<inf loc="post">2</inf>-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">84%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">76:24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">76%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">64%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2,4-(OMe)<inf loc="post">2</inf>-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">47%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83:17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-(OMe)<inf loc="post">2</inf>-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">65%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83:17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">74%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">95:5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">96%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">93%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-CH(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">48%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">35:65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−1%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-NHPh</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">24%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">14:86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">23%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">86%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">46:54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">79%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">77%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">59%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">88:12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">74%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.70</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">61%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.68</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Bn)(Ph)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">93%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">44:56</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">71%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">73%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">86%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91:9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">49%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">40%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">29%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">80:20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">40%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.98</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">40%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">24%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">49:51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−3%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">47%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">33:67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">32%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">59:41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">93%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">45:55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">82%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−1%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">52%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−15%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-F-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">87%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">77:23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>31</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-OMe-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">72%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">80:20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">13%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-Br-Ph-</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">49%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">76:24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>33</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">59%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">85:15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">96%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">96%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">n.d.</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>34</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">40%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">96:4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">97%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">99%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">n.d.</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>35</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">72%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">92:8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">17%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>36</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">49%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91:9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">93%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">n.d.</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>37</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-OCF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">100:0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">61%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">40%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">21.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-N(Ph)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">100:0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">100%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">95%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">92:8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.57</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>40</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30:70</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">77%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">79%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>41</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">47%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">25:75</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">11%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>42</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">21:79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">92%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.49</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">93%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>43</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Piperidine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">51%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">41:59</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">94%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">85%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>44</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">77%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">26:74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">78%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>45</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">12%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30:70</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">66%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">61%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>46</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">56%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">26:74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>-</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>47</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">10%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">17:83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">88%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>48</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-OCF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">83%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">12:88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">54%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">40%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.49</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>49</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-OMe</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">32%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">38:62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">72%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">64%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.93</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>50</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">-Morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5-I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">57%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30:70</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">95%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">95%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CNS+</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Standard compound Lrrk2-in-1: IC<ce:inf loc="post">50</ce:inf> values: 0.02 μM and 0.02 μM in LRRK2 and LRRK2 G2019S respectively.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523417305147-d50e542e49da222a8b05c55f6c4fa592">
                  <ce:given-name>Irene G.</ce:given-name>
                  <ce:surname>Salado</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0015">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523417305147-640653ae924378ee8d31d98bea4d4e79">
                  <ce:given-name>Josefa</ce:given-name>
                  <ce:surname>Zaldivar-Diez</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0020">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0025">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523417305147-f2ee189f545015c525e77defdeff8c09">
                  <ce:given-name>Víctor</ce:given-name>
                  <ce:surname>Sebastián-Pérez</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0030">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523417305147-ad242f40cbd1245c6dc11e5e8a82ac5c">
                  <ce:given-name>Lingling</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0035">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523417305147-ae98638dd8a8d24875c4bb45424a277e">
                  <ce:given-name>Larissa</ce:given-name>
                  <ce:surname>Geiger</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0040">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523417305147-3427e438995775b7af8afdea06e784dd">
                  <ce:given-name>Silvia</ce:given-name>
                  <ce:surname>González</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0045">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523417305147-b0698f6c45f2fc130406e9e41d83d939">
                  <ce:given-name>Nuria E.</ce:given-name>
                  <ce:surname>Campillo</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0050">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523417305147-fe8634eb18b54b3596aa33c5def07175">
                  <ce:given-name>Carmen</ce:given-name>
                  <ce:surname>Gil</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0055">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523417305147-0d6fc98ddfd2f96f44ca1abdb29b90ee">
                  <ce:given-name>Aixa V.</ce:given-name>
                  <ce:surname>Morales</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0060">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523417305147-5000961f97cdc044b7bc97e015319984">
                  <ce:given-name>Daniel I.</ce:given-name>
                  <ce:surname>Perez</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0065">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor2" id="crosref0070">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au11" orcid="0000-0002-2707-8110" author-id="S0223523417305147-4a0cfd0bfc951d79e5fa2e3c1d2d6e2c">
                  <ce:given-name>Ana</ce:given-name>
                  <ce:surname>Martinez</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0075">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0080">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Department of Chemical and Physical Biology, Centro de Investigaciones Biológicas-CSIC, Madrid, Spain</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Chemical and Physical Biology</sa:organization>
                     <sa:organization>Centro de Investigaciones Biológicas-CSIC</sa:organization>
                     <sa:city>Madrid</sa:city>
                     <sa:country>Spain</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal-CSIC, Madrid, Spain</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Molecular, Cellular and Developmental Neurobiology</sa:organization>
                     <sa:organization>Instituto Cajal-CSIC</sa:organization>
                     <sa:city>Madrid</sa:city>
                     <sa:country>Spain</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Equally contributed to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="4" month="5" year="2017"/></ce:date-received>
            <ce:date-revised day="27" month="6" year="2017"/></ce:date-revised>
            <ce:date-accepted day="28" month="6" year="2017"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Leucine-rich repeat kinase 2 (LRRK2) is one of the most pursued targets for Parkinson's disease (PD) therapy. Moreover, it has recently described its role in regulating Wnt signaling and thus, it may be involved in adult neurogenesis. This new hypothesis could give rise to double disease-modifying agents firstly by the benefits of inhibiting LRRK2 and secondly by promoting adult neurogenesis. Herein we report, the design, synthesis, biological evaluation, SAR and potential binding mode of indoline-like LRRK2 inhibitors and their preliminary neurogenic effect in neural precursor cells isolated from adult mice ventricular-subventricular zone. These results open new therapeutic horizons for the use of LRRK2 inhibitors as neuroregenerative agents. Moreover, the indolinone derivatives here prepared, inhibitors of the kinase activity of LRRK2, may be considered as pharmacological probes to study the potential neuroregeneration of the damaged brain.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417305147/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>LRRK2 inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Protein kinase inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Indolinone</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Adult neurogenesis</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Neural stem cell</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>Regenerative medicine</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">The search of effective treatments for neurodegenerative diseases is one of the urgent clinical and social needs today given their widespread and devastating nature. As most neurodegenerative disorders are age-dependent, due to longer life expectancy the prevalence of these diseases, including Alzheimer's and Parkinson's disease among others, increases daily. Common characteristics of neurodegenerative diseases include the progressive loss of neurons in specific regions of the nervous system underlying the subsequent decline in cognitive or motor function in patients. Given their largely unknown etiology and the lack of effective treatments there is a critical need to better understand the underlying disease pathophysiology and discover effective disease-modifying targets for their treatment.</ce:para>
                  <ce:para id="p0040" view="all">Genetic studies carried on several families in Asia, the United States, and Europe led to discover in 2004 that mutations in the gene <ce:italic>LRRK2</ce:italic> encoding leucine-rich repeat kinase 2 (LRRK2) as a major genetic risk factor for both familial and sporadic Parkinson's disease (PD) <ce:cross-ref refid="bib1" id="crosref0085">[1]</ce:cross-ref>. Up to date among the disease-linked genetic polymorphisms (15% of the total PD population) LRRK2 mutations account for 4% of the cases and 1% of the sporadic ones <ce:cross-ref refid="bib2" id="crosref0090">[2]</ce:cross-ref>. Although these incidences are quite low and it remains unclear how mutations in <ce:italic>LRRK2</ce:italic> gene cause PD-related neurodegeneration, LRRK2 has raised as one of the most pursued targets for PD and its inhibition has been proposed to be beneficial for preventing neurodegeneration. Big efforts are being done at the moment both from academia and the pharmaceutical industry with the goal of developing selective and brain-permeable LRRK2 inhibitors as neuroprotective agents for PD <ce:cross-refs refid="bib3 bib4" id="crosrefs0010">[3,4]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0045" view="all">LRRK2 is an unusually large (2527 amino acids) protein that is classified as a member of the Ras-like GTPase (ROCO) superfamily. At least 6 independent domains have been established including a kinase domain, a GTPase domain and several protein-protein interacting regions <ce:cross-ref refid="bib5" id="crosref0095">[5]</ce:cross-ref>. The physiological role of LRRK2 is poorly understood and many of its substrates remain unclear, however, great success was achieved by the identification of a subset of Rab GTPases as key LRRK2 substrates <ce:cross-ref refid="bib6" id="crosref0100">[6]</ce:cross-ref>. The downstream signals in which LRRK2 is involved are not well characterized yet, however LRRK2 can be related to other pathological pathways outside the direct PD pathology. LRRK2 can be related to tau pathology, inflammatory response, oxidative stress, mitochondrial and synaptic dysfunction, deficiencies in the autophagy-lysosomal system <ce:cross-ref refid="bib7" id="crosref0105">[7]</ce:cross-ref> and its implication in adult neurogenesis through the Wnt signaling pathway <ce:cross-ref refid="bib8" id="crosref0110">[8]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0050" view="all">Among these connections we considered as the most interesting one, the hypothesis that the pharmacological inhibition of LRRK2 may induce adult neurogenesis. There is evidence suggesting that neurogenesis is impaired in many neurodegenerative diseases, therapeutic approaches that stimulate neurogenesis may have potential to stimulate repair and even recovery, thereby providing innovative, disease-modifying treatments <ce:cross-refs refid="bib9 bib10" id="crosrefs0015">[9,10]</ce:cross-refs>. Therefore, LRRK2 inhibitors may have a dual therapeutic role: the first one due to the direct beneficial effect of LRRK2 inhibition and the second one as enhancing adult neurogenesis.</ce:para>
                  <ce:para id="p0055" view="all">Based on these collective observations pointing to the critical role of LRRK2 in CNS function and connections to proneurogenic pathways like Wnt signaling <ce:cross-ref refid="bib8" id="crosref0115">[8]</ce:cross-ref>, we initiated a medicinal chemistry program with the aim of finding new selective LRRK2 inhibitors with physicochemical properties compatible with crossing the blood brain barrier (BBB). Furthermore, we have used them as pharmacological probes of adult neurogenesis activators using neural stem cells isolated from the neurogenic niche of the adult mouse ventricular-subventricular zone <ce:cross-ref refid="bib11" id="crosref0120">[11]</ce:cross-ref>. In this communication we present a class of outstanding novel LRRK2 inhibitors that show a preliminary effect in increasing the proliferation of neural stem cells from the subventricular zone of adult mice and can therefore be considered as chemical probes to study the neuroregeneration potential of the damaged brain.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Design of new compounds</ce:section-title>
                     <ce:para id="p0060" view="all">Biology-oriented synthesis <ce:cross-ref refid="bib12" id="crosref0125">[12]</ce:cross-ref> employs chemical privileged scaffolds from natural sources for the development of focused libraries because natural products are particularly important as source of inspiration for new compounds <ce:cross-ref refid="bib13" id="crosref0130">[13]</ce:cross-ref>. A literature survey identified several isatin (1<ce:italic>H</ce:italic>-indole-2,3-dione) derivatives as, a natural scaffold present in different Chinese traditional medicines, with potent biological activity on different protein kinases (<ce:cross-ref refid="fig1" id="crosref0135">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>) <ce:cross-ref refid="bib14" id="crosref0140">[14]</ce:cross-ref>. Moreover, some of them such as sunitinib are FDA approved for human therapy while semaxanib is currently in clinical trials (<ce:cross-ref refid="fig1" id="crosref0145">Fig. 1</ce:cross-ref>) <ce:cross-ref refid="bib15" id="crosref0150">[15]</ce:cross-ref>.</ce:para>
                     <ce:para id="p0065" view="all">For the design of new LRRK2 inhibitors, we decided to keep the indolinone ring as common and privileged scaffold and to modify the nature of the atom directly joined to the oxindole ring introducing a nitrogen atom instead of the carbon atom present in the compounds of <ce:cross-ref refid="fig1" id="crosref0155">Fig. 1</ce:cross-ref>. Furthermore, the influence of various substituents on the aryl group was explored obtaining different compounds, with aromatic and aliphatic nature. In addition, the linker between the above mentioned substituent and the oxoindole heterocycle was modified. Imines and hydrazones were used for this purpose. Finally, alkylation of the heterocyclic nitrogen atom and substitution in different positions of the indolinone framework gave additional diversity to the final compounds (<ce:cross-ref refid="fig2" id="crosref0160">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Chemistry</ce:section-title>
                     <ce:para id="p0070" view="all">Preparation of the first family of these compounds was carried out using classical conditions to conduct the imine formation reaction between the isatin core and the corresponding aromatic amine under reflux in toluene and with 4-toluensulfonic acid as catalyst <ce:cross-ref refid="bib16" id="crosref0165">[16]</ce:cross-ref>. Several imino indolinone derivatives have been previously described. However, due to long reaction times and low yields, new synthetic reaction conditions were looked for. Microwave assisted organic synthesis in the absence of solvent and montmorillonite (MMT-K10) as surface catalyst were the best option found <ce:cross-ref refid="bib17" id="crosref0170">[17]</ce:cross-ref>, although here an optimized work-up was used (described in the experimental part). MMT-K10 is a mixture of silicates in laminar arrangement recently used as inorganic base in organic synthesis. The reactions catalysed by MMT-K10 are normally performed under mild conditions to obtain high yield and selectivity. MMT-K10 was not only used as a base but also as a solid surface where the reaction took place <ce:cross-ref refid="bib18" id="crosref0175">[18]</ce:cross-ref>. For imine formation it is essential to remove the water from the reaction medium and normally 4-toluenesulfonic acid was used. In our case, the use of microwave assisted organic synthesis accelerates the dehydration of the reaction using a clay support MMT-K10. Thus, lower reaction times (10 min) and an increase in general yield was achieved except for compounds <ce:bold>7</ce:bold> and <ce:bold>9</ce:bold> where the amine employed was in the hydrochloride form. Following this optimized procedure, compounds <ce:bold>1–15</ce:bold> were isolated (<ce:cross-ref refid="sch1" id="crosref0180">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0075" view="all">The second family of compounds bears in their chemical structure aliphatic cyclic scaffolds as piperidine, morpholine or diphenylhydrazine among others (<ce:bold>16–21</ce:bold>) instead of a phenyl ring. This involves a change in the nature of the linker to the isatin core from an imino to a hydrazone one (<ce:cross-ref refid="sch1" id="crosref0185">Scheme 1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0080" view="all">In order to explore the importance of the nitrogen atom of the isatin derivative, we <ce:italic>N</ce:italic>-alkylated the previously synthetized compounds employing classical conditions <ce:cross-ref refid="bib19" id="crosref0190">[19]</ce:cross-ref> which led us to derivatives <ce:bold>22–27</ce:bold>. Nevertheless, in the case of imine derivatives, acidic medium leads to the hydrolysis of the imine bond. For this reason, the <ce:italic>N</ce:italic>-alkylation of the isatin heterocycle was done previously to the imine formation leading to compounds <ce:bold>28–29</ce:bold>. Further reactions with different anilines yielded the desired compounds <ce:bold>30–32</ce:bold> (<ce:cross-ref refid="sch1" id="crosref0195">Scheme 1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0085" view="all">Finally, to introduce an alternative diversity point, the isatin core with different substituents in positions 5 and 7 were used as starting materials leading to the final products <ce:bold>33–50</ce:bold>.</ce:para>
                     <ce:para id="p0090" view="all">All the synthesized compounds were carefully characterized by mass spectra (MS), <ce:sup loc="pre">1</ce:sup>H and <ce:sup loc="pre">13</ce:sup>C-NMR including bidimensional HMBC and HSQC experiments, and when possible for some previously described compounds, melting points were compared (see experimental). Elemental analysis was performed for all the new herein reported compounds (see supporting information <ce:cross-ref refid="appsec2" id="crosref0200">Table S1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0095" view="all">The indolinones with imino or hydrazone bond directly attached to the heterocyclic framework may present two different isomers <ce:italic>E</ce:italic> and <ce:italic>Z</ce:italic> that were identified and quantified by <ce:sup loc="pre">1</ce:sup>H-NMR (<ce:cross-ref refid="tbl1" id="crosref0205">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>). In order to determine the main isomer, a nuclear Overhauser effect (nOe) experiment was carried out. Thus, by irradiation performed in the indolinone H4 proton, a nOe effect of the aromatic protons of the phenyl ring is observed for the <ce:italic>E</ce:italic>-isomer, while it is not detected for the <ce:italic>Z</ce:italic>-isomer (<ce:cross-ref refid="fig3" id="crosref0210">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>). This methodology was carried out in all the cases to determine the isomers ratio of the compounds. For the first family of synthesized compounds, the oxoindole iminoderivatives <ce:bold>1</ce:bold>–<ce:bold>15</ce:bold> and <ce:bold>30–32,</ce:bold> the main isomer obtained was the <ce:italic>E</ce:italic> form although the <ce:italic>Z</ce:italic> one was also detected. Differences observed in the isomers ratio could be justify by the electron donor or electron acceptor substituents present on the phenyl ring. However for compounds <ce:bold>17</ce:bold> and <ce:bold>18</ce:bold>, the main isomer was found to be the <ce:italic>Z</ce:italic> one. In these compounds an intramolecular hydrogen bond could be formed between the carbonyl group of the indolinone core and the CH or NH of the imino or hydrazine bond, respectively.</ce:para>
                     <ce:para id="p0100" view="all">In compounds where the hydrazone linker was present (derivatives <ce:bold>16</ce:bold>, <ce:bold>19</ce:bold>–<ce:bold>27</ce:bold>, <ce:bold>33</ce:bold>–<ce:bold>38</ce:bold>), nOe experiments revealed that the main and in some cases such as compounds <ce:bold>37</ce:bold> and <ce:bold>38</ce:bold>, the only isomer obtained was the <ce:italic>E</ce:italic> one due to the hydrogen bond formation between the H4 proton of the indolinone core and the nitrogen atom of the hydrazone moiety. If any substituents are present in the indolinone heterocycle, their piperidine (<ce:bold>39–43</ce:bold>) or morpholine (<ce:bold>44–50</ce:bold>) derivatives lead to obtain the <ce:italic>Z</ce:italic> isomer as the majority. However, when there is no substitution in the oxoindole core, both isomers <ce:italic>E</ce:italic> and <ce:italic>Z</ce:italic> are found in the same ratios (see compounds <ce:bold>19</ce:bold>, <ce:bold>24</ce:bold>, <ce:bold>26</ce:bold>, <ce:bold>27</ce:bold>) (<ce:cross-ref refid="tbl1" id="crosref0215">Table 1</ce:cross-ref>). Some representative <ce:sup loc="pre">1</ce:sup>H-NMR spectra are collected in the supplementary information (<ce:cross-ref refid="appsec2" id="crosref0220">Fig. S1</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Kinase inhibition activity evaluation</ce:section-title>
                     <ce:para id="p0105" view="all">All the synthetized indolinone compounds were evaluated as potential inhibitors of LRRK2. The assays were performed using LifeTechnologies Adapta<ce:sup loc="post">®</ce:sup> methodology according to the procedure described in the experimental section. This is a fluorescent-based immunoassay for the detection of ADP formed by the kinase reaction. Human recombinant LRRK2 and its substrate known as LRRKtide peptide (sequence: RLGRDKYKTLRQIRQ) were incubated in the presence or absence of inhibitors, and the ADP formed was quantified using specific antibodies resulting in a TR-FRET signal variation. All the compounds were assayed twice at a fixed concentration of 10 μM using the commercial compound lrrk2-in-1 as reference standard. When the percentage of inhibition was more than 50%, the dose response curve was determined and the IC<ce:inf loc="post">50</ce:inf> value calculated. Moreover, compounds that inhibit LRRK2 were also assayed in human recombinant LRRK2 G2019S, the most common LRRK2 mutation in familial PD patients <ce:cross-ref refid="bib20" id="crosref0225">[20]</ce:cross-ref>, following the same protocol. This mutation results in an increase of kinase activity that is linked to the severity degree of the pathology <ce:cross-ref refid="bib21" id="crosref0230">[21]</ce:cross-ref>. Some of the compounds here synthesized showed a marked inhibition on LRRK2 and LRRK2 G2019S with IC<ce:inf loc="post">50</ce:inf> values in the nano/submicro molar range, similar to the reference compound lrrk2-in-1. Generally, if a compound was able to inhibit LRRK2, it was also able to inhibit this mutated form with similar potency even with PD-linked mutation being located in activation loop <ce:cross-ref refid="bib22" id="crosref0235">[22]</ce:cross-ref>. All the data are collected in <ce:cross-ref refid="tbl1" id="crosref0240">Table 1</ce:cross-ref>.</ce:para>
                     <ce:para id="p0110" view="all">Since one of the main challenges in kinase inhibitor discovery is the selectivity, and being aware that the central scaffold of our compounds is also present in other protein kinase inhibitors (<ce:cross-ref refid="fig1" id="crosref0245">Fig. 1</ce:cross-ref>), we performed a kinase profiling with the first indolinone-like LRRK2 inhibitor here prepared (<ce:bold>16</ce:bold>) with an IC<ce:inf loc="post">50</ce:inf> value in the submicromolar range (IC<ce:inf loc="post">50</ce:inf> = 0.11 μM) to be sure that we are working with selective LRRK2 inhibitors. We selected a panel of fifty different human protein kinases and tested the compound at a fixed concentration of 10 μM. In this panel, those kinases previously inhibited by different compounds containing the indolinone framework, as those depicted in <ce:cross-ref refid="fig1" id="crosref0250">Fig. 1</ce:cross-ref>, were included. Thus the inhibitory activity on different CK1 isoforms and EGFR, IGF1R and PDGFR alpha as representatives of tyrosin kinases were evaluated. Detailed experimental background such as ATP concentration and quantity of each enzyme used are described in the supporting information (<ce:cross-ref refid="appsec2" id="crosref0255">Table S2</ce:cross-ref>). Selected protein kinases and the percentage of kinase activity remained after compound <ce:bold>16</ce:bold> treatment is depicted in <ce:cross-ref refid="fig4" id="crosref0260">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>. High selectivity towards LRRK2 inhibition was observed for indolinone derivative <ce:bold>16</ce:bold>, which only showed a slight inhibition on the FMS-like tyrosine kinase 3 (FLT-3), pointing to a selective family of inhibitors. FLT-3 is involved and aberrantly active in acute myeloid leukemia <ce:cross-ref refid="bib23" id="crosref0265">[23]</ce:cross-ref>. To assure this selectivity profile, a second indolinone was selected to run the same panel. In that case, our criteria were to be a potent inhibitor and to have good drug like properties such the permeability in the central nervous system (CNS). Kinase selectivity for this family of compounds was confirmed when the isatin-like compound <ce:bold>38</ce:bold> was used (<ce:cross-ref refid="fig4" id="crosref0270">Fig. 4</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Structure-activity relationships and molecular modeling studies</ce:section-title>
                     <ce:para id="p0115" view="all">These first results revealed clear structure-activity relationships providing important clues for further optimization. Among the 3-phenylimino-indolinone derivatives, substitution position in the phenyl ring was critical for activity. Only para-substituents were tolerated. Inhibition of LRRK2 was found for derivatives <ce:bold>2</ce:bold> and <ce:bold>10–13</ce:bold>, all of them with different chemical moieties in position 4 of the phenyl ring. By contrast, there was a lack of potency when these substituents are in orto- and/or meta-position (compounds <ce:bold>1, 5–9, 14–15</ce:bold>). An exception was observed in indolinone <ce:bold>8</ce:bold> with a fluorine atom attached in orto-position to the phenyl ring. This compound had an IC<ce:inf loc="post">50</ce:inf> value of 2.34 μM, which is in the same range to that of derivative <ce:bold>4</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 3.65 μM) in which the phenyl ring is not substituted. That may be explained by the similarity of the size of fluorine atom to that of the hydrogen one.</ce:para>
                     <ce:para id="p0120" view="all">More effective for kinase inhibition was the introduction of a hydrazone spacer instead the imino linker. In those cases an increase in the inhibition of LRRK2 was observed (compounds <ce:bold>16, 19–21</ce:bold> 
                        <ce:italic>versus</ce:italic> 
                        <ce:bold>1–15</ce:bold>). This effect was clearly revealed by the submicromolar activity of indolinone <ce:bold>16</ce:bold> and the complete lack of activity of compound <ce:bold>17</ce:bold>. The only difference between these two compounds was the replacement of a carbon atom by a nitrogen one, resulting in the shifting from imino to hydrazone moiety.</ce:para>
                     <ce:para id="p0125" view="all">Regarding the indolinone ring, greater variations in the biological activity were found when different modifications in this heterocyclic core are introduced. For example, the NH group was completely necessary for LRRK2 inhibition and when it was modified by alkylation, kinase inhibition was lost or decreased by more than one order of magnitude (compounds <ce:bold>23–27</ce:bold> and <ce:bold>31</ce:bold> 
                        <ce:italic>versus</ce:italic> indolinones <ce:bold>16, 19, 20</ce:bold> and <ce:bold>2</ce:bold>). Substitution in position 7 of the heterocyclic core completely abolished activity of compounds <ce:bold>35, 41</ce:bold> and <ce:bold>46</ce:bold>, presumably causing the loss of interaction with LRRK2. However, an increase in the inhibition potency was found when position 5 of indolinone framework was modified by different chemical groups such as halides or different ethers (compounds <ce:bold>33, 34, 36–40, 42–45, 47–50</ce:bold>). In some cases, such as compounds <ce:bold>33, 34</ce:bold> and <ce:bold>36,</ce:bold> we obtained very potent LRRK2 inhibitors with IC<ce:inf loc="post">50</ce:inf> values in the low two digit nanomolar range.</ce:para>
                     <ce:para id="p0130" view="all">In order to gain insight into the binding mode of this new family of potent LRRK2 inhibitors, and looking for clues to assist in the lead-to-candidate optimization, a docking study using Glide XP (Schrödinger suite program) that allows examining a potential binding mode to the enzyme was carried out. The kinase domain of LRRK2 has not been crystallized but a LRRK2 homology model has recently been published <ce:cross-ref refid="bib24" id="crosref0275">[24]</ce:cross-ref>. We reproduced the LRRK2 homology model using the crystal structure of Janus Kinase 2 as template and the human LRRK2 sequence retrieved from Swiss-Prot (see supplementary material) following the published protocol.</ce:para>
                     <ce:para id="p0135" view="all">All the compounds showed a similar binding mode in the catalytic site of LRRK2. In <ce:cross-ref refid="fig5" id="crosref0280">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>A the docking of indolinone <ce:bold>33</ce:bold> is shown, as a representative example. The most important interaction was governed by the dual hydrogen bond between Lys 1906 and two features of the indolinone ring: the carbonyl group in position 2 and the nitrogen atom of the hydrazine attached to the heterocycle. This molecular orientation allowed both the formation of a halogen bond between the Asp1887 and the halide atom in position 5 of the indolinone, and the possibility of a hydrogen bond between the Asp 2017 and the heterocyclic NH. This binding mode with the same molecule orientation and key interactions was also present in compounds with piperidine (<ce:bold>39</ce:bold>) or morpholine in the hydrazone linker (<ce:cross-ref refid="fig5" id="crosref0285">Fig. 5</ce:cross-ref>B). This binding mode might explain the better value of activity of those compounds with chemical groups in position 5.</ce:para>
                     <ce:para id="p0140" view="all">Considering the protein surface and druggable cavities, in the catalytic site exits two pockets where additional van der Waals interactions with the ligand may increase enzymatic potency. The first one at the back of Lys 1906 and Glu 1920 was fully occupied with one of the phenyl rings of diphenyl amino compounds that may be responsible for the higher potency of these derivatives in comparison with their piperidine and morpholine analogs. However, the six-membered ring present in these last compounds was oriented totally towards the second cavity, pointing to a new direction where current molecules may be modified to potentially increase hydrophobic interactions (<ce:cross-ref refid="fig6" id="crosref0290">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">Prediction of blood brain barrier (BBB) permeability</ce:section-title>
                     <ce:para id="p0145" view="all">As one of the main obstacles for the treatment of the diseases of the central nervous system (CNS) is the drug's penetration into the blood-brain barrier (BBB) at therapeutic concentrations, we decided to explore the prediction of our top indolinone-based LRRK2 inhibitors to penetrate into the human BBB. Parallel artificial membrane permeability assay (PAMPA) is a high-throughput technique developed to predict passive permeability through biological membranes <ce:cross-ref refid="bib25" id="crosref0295">[25]</ce:cross-ref>, and we used this methodology to evaluate the BBB permeability of our LRRK2 inhibitors. The first step consists of an assay validation comparing the human reported permeabilities (<ce:italic>P</ce:italic>e) values of several marketed drugs with the experimental data obtained by using this methodology (<ce:cross-ref refid="appsec2" id="crosref0300">Fig. S2</ce:cross-ref> supporting information). A good correlation between experimental-described values was obtained <ce:italic>P</ce:italic>e (exp) = 1.1324 <ce:italic>P</ce:italic>e (bibl.) = 1.0056 (R<ce:sup loc="post">2</ce:sup> = 0.9689). From this equation and following the pattern established in the literature for BBB permeation prediction <ce:cross-ref refid="bib26" id="crosref0305">[26]</ce:cross-ref>, we could classify compounds as CNS + when they present a permeability >3.54 × 10<ce:sup loc="post">−6</ce:sup> cm s<ce:sup loc="post">−1</ce:sup>. The <ce:italic>in vitro</ce:italic> permeabilities (<ce:italic>P</ce:italic>e) of commercial drugs through lipid membrane extract together with those belonging to indolinones derivatives were determined as described in <ce:cross-ref refid="tbl1" id="crosref0310">Table 1</ce:cross-ref> and Supporting information <ce:cross-ref refid="appsec2" id="crosref0315">Table S3</ce:cross-ref>. Although calculated prediction to cross the BBB was positive for all the compounds, solubility problems were encountered for compounds <ce:bold>33, 34</ce:bold> and <ce:bold>36</ce:bold> and the prediction of BBB permeability was not possible to be determined. The low solubility of these compounds may be explained considering the predicted values of octanol/water partition coefficient (log p), polar surface area (PSA) and aqueous solubility (log S) calculated by QuickPro program for compounds <ce:bold>33, 34, 36</ce:bold> and <ce:bold>38</ce:bold> (see supporting information <ce:cross-ref refid="appsec2" id="crosref0320">Table S4</ce:cross-ref>). More than one order of magnitude was found in log S between <ce:bold>38</ce:bold> and <ce:bold>33, 34</ce:bold> and <ce:bold>36</ce:bold> although their chemical structures are very similar, pointing to a better solubility for derivative <ce:bold>38.</ce:bold> Thus, as many of the LRRK2 inhibitors tested are predicted to cross the BBB by PAMPA assay they have potential for further pharmaceutical development including <ce:italic>in vivo</ce:italic> studies of CNS diseases.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">Neurogenic properties of LRRK2 inhibitors</ce:section-title>
                     <ce:para id="p0150" view="all">Adult NSCs continuously generate neurons throughout life in two brain regions: the subgranular zone of the hippocampus and the V-SVZ, adjacent to the lateral ventricles. The V-SVZ is the largest germinal region in the adult mammalian brain and generates olfactory bulb interneurons and oligodendrocytes and in the case of the human brain, it could also be the source of neuroblasts and interneurons found in the adjacent striatum <ce:cross-ref refid="bib27" id="crosref0325">[27]</ce:cross-ref>. Thus, the finding of new molecules able to increase the neurogenic potential of the VZ-SVZ niche, especially in the case of PD patients with alterations in LRRK2 activity, is of great relevance.</ce:para>
                     <ce:para id="p0155" view="all">To determine if some of the LRKK2 inhibitors described in <ce:cross-ref refid="tbl1" id="crosref0330">Table 1</ce:cross-ref> could have an impact on neurogenesis we selected five indolinone-like LRRK2 inhibitors taking in consideration enzymatic activity, solubility properties, compound availability and chemical diversity. In total, piperidine, morpholine and diphenylamino substituents of the hydrazine moiety were present in compounds <ce:bold>19, 20, 38, 44</ce:bold> and <ce:bold>45</ce:bold>, selected for these studies.</ce:para>
                     <ce:para id="p0160" view="all">As NSCs and neural progenitors cultured <ce:italic>in vitro</ce:italic> have the ability to grow as spheres <ce:cross-ref refid="bib28" id="crosref0335">[28]</ce:cross-ref>, we used primary NSCs and neural progenitors isolated from the subventricular zone of adult mice and cultured them in the presence or absence of the above mentioned compounds at a fixed concentration of 5 μM. We investigated whether addition of indolinone-like LRRK2 inhibitors impacted the formation of neurospheres after the dissociated NSCs and neural progenitors were growing for 3 days in the presence of mitogens (FGF and EGF). As shown in <ce:cross-ref refid="fig7" id="crosref0340">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>, the size of neurospheres (estimated as total area of the neurospheres) was significantly higher in those cultures treated with the selected small molecules (indolinones <ce:bold>19, 20, 38, 44</ce:bold> and <ce:bold>45</ce:bold>), compared to controls treated with DMSO (<ce:cross-ref refid="fig7" id="crosref0345">Fig. 7</ce:cross-ref>C; control normalized: 100 ± 16.7%; LRRK inhibitors from 118.5 ± 5% (compound <ce:bold>38</ce:bold>) to 141.5 ± 9% (indolinone <ce:bold>45</ce:bold>). This increase of up to 1.4-fold in the total area of the formed neurospheres could be related to an increase in the size of individual neurospheres due to an increase in proliferation or to an increase in the number of neurospheres caused by an increase in the number of cells with the ability to form neurospheres. The number of neurospheres formed in the presence of the tested LRRK2 inhibitors was similar to those formed in control conditions (<ce:cross-ref refid="fig7" id="crosref0350">Fig. 7</ce:cross-ref>D). Thus, the inhibition of LRRK2, using specific indolinone-derivatives, promotes the proliferation of NSCs and neural progenitors from adult SVZ grown as neurospheres.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0070">Conclusions</ce:section-title>
                  <ce:para id="p0165" view="all">LRRK2, an enigmatic enzyme implicated in both familial and idiopathic PD risk, may be also play an important role in adult neurogenesis through the Wnt signaling pathway.</ce:para>
                  <ce:para id="p0170" view="all">Since the discovery of the adult neurogenesis great research efforts have been made to decipher its role and implications in health and pathological conditions. Currently, it is recognized that aging, neurodegenerative and some mental diseases are associated with a decrease in brain neurogenesis, although the exact relevance of this decrease to disease etiology and pathogenesis remains debated. Thus, small molecules able to modulate neurogenesis and neuroplasticity, are intensively being pursued as valuable pharmacological probes and as new potential therapeutic agents for these unmet conditions or diseases <ce:cross-ref refid="bib29" id="crosref0355">[29]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0175" view="all">With the aim of translating these discoveries into therapeutics, we have designed new indoline-derived LRRK2 inhibitors with predicted brain permeability and determine their potential as regulators of adult neurogenesis in neural stem cells isolated from the ventricular-subventricular zone. Therefore, these inhibitors of the activity of LRRK2 may be considered as pharmacological probes to study the potential neuroregeneration of the damaged brain. Further studies are in progress to show the regenerative potential of LRRK2 inhibitors in <ce:italic>in vivo</ce:italic> models.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0075">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0080">Chemistry</ce:section-title>
                     <ce:para id="p0180" view="all">Reagents were purchased from commercial sources and used without further purification. Melting points were determined with a Mettler Toledo MP70 apparatus. Crude residues were purified with the indicated solvent as eluent by flash column chromatography carried out at medium pressure using silica gel (E. Merck, Grade 60, particle size 0.040–0.063 mm, 230–240 mesh ASTM) or IsoleraOne flash purification system from Biotage. Compounds were detected with UV light (254 nm). <ce:sup loc="pre">1</ce:sup>H-NMR spectra were obtained on the Bruker AVANCE-300 spectrometer working at 300 MHz or on a Varian INOVA 400 spectrometer working at 400 MHz. Typical spectral parameters: spectral width 16 ppm, pulse width 9 μs (57°), data size 32 K. <ce:sup loc="pre">13</ce:sup>C-NMR experiments were carried out on the Bruker AVANCE-300 spectrometer operating at 75 MHz or on a Varian INOVA 400 spectrometer working at 100 MHz. The acquisition parameters: spectral width 16 kHz, acquisition time 0.99 s, pulse width 9 μs (57°), data size 32 K. Chemical shifts are reported in values (ppm) relative to internal Me<ce:inf loc="post">4</ce:inf>Si and <ce:italic>J</ce:italic> values are reported in Hz. HPLC analyses were performed on Alliance Waters 2690 equipment, with a UV detector photodiode array Waters 2996 with MS detector MicromassZQ (Waters), using an Sunfire column C18, 3.5 μm (50 mm × 4.6 mm) and acetonitrile and MilliQ water (with 0.1% formic acid) as mobile phase. The standard gradient consisted of a 5 min run from 15% to 95% of acetonitrile at a flow rate of 1 mL/min. Elemental analyses were performed by the analytical department at CENQUIOR (CSIC), and the results obtained were within ±0.4% of the theoretical values. The microwave assisted syntheses were carried out using a Biotage Initiator eight single-mode cavity instrument from Biotage. Experiments were performed with temperature control mode in sealed microwave process vials. The temperature was measured with an IR sensor on the outside of the reaction vessel. Stirring was provided by an <ce:italic>in situ</ce:italic> magnetic stirrer.</ce:para>
                     <ce:para id="p0185" view="all">
                        <ce:bold>
                           <ce:italic>General procedure for compounds 1–21, 30–50:</ce:italic>
                        </ce:bold> Following the procedure described by Pandey et al. <ce:cross-ref refid="bib17" id="crosref0360">[17]</ce:cross-ref> with some modifications. A mixture of the isatin derivative (1 eq), the corresponding amine derivative (1 eq) and MMT-K10 (20 mg for 1 mmol of the isatin derivative) and toluene if necessary, was heated under microwave irradiation (6–90 min, 100–110 °C). After cooling to room temperature, ethyl acetate (50 mL) was added and the mixture was extracted with a saturated solution of NaHCO<ce:inf loc="post">3</ce:inf> (50 mL x 3). Finally, the organic phase was dried over magnesium sulfate and the solvent evaporated under reduced pressure. The residue was chromatographed as indicated in each case.</ce:para>
                     <ce:para id="p0190" view="all">In case the amine was in hydrochloride form, the amine derivative (1 eq) was stirred with triethylamine (1 eq) and toluene (3 mL) for 1 h at room temperature.</ce:para>
                     <ce:para id="p0195" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((3-Nitrophenyl)imino)indolin-2-one (1)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 3-nitroaniline (234.7 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 15 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (226.1 mg, 50%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 63:37, mp: 217–218 °C. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.98 (s, 1 H), 8.10 (ddd, <ce:italic>J</ce:italic> = 8.1, 2.2, 0.9 Hz, 1H), 7.85 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.75 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.51–7.41 (m, 1H), 7.36 (td, <ce:italic>J</ce:italic> = 7.8, 1.2 Hz, 1H), 6.90 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 6.72 (td, <ce:italic>J</ce:italic> = 7.7, 1.0 Hz, 1H), 6.34 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 163.9, 157.1, 152.1, 149.4, 148.2, 135.7, 131.9, 126.4, 125.2, 122.6, 120.2, 116.3, 113.0, 112.4. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.98 (s, 1H), 7.95 (ddd, <ce:italic>J</ce:italic> = 8.2, 2.4, 1.0 Hz, 1H), 7.85 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.61 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 7.59 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.51–7.41 (m, 1H), 7.07 (td, <ce:italic>J</ce:italic> = 7.5, 0.6 Hz, 1H), 6.87 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.2, 155.5, 151.3, 148.6, 147.2, 135.5, 130.5, 126.4, 124.0, 123.1, 121.6, 119.3, 114.2, 111.7. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 268 [M+H]. Anal. C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">9</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0200" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((4-Methoxyphenyl)imino)indolin-2-one (2)</ce:bold>: Reagents: isatin (600 mg, 4.1 mmol), 4-methoxyaniline (502.3 mg, 4.1 mmol), MMT-K10 (81.6 mg) and toluene (1 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by column cromatography (chloroform/methanol 10:1) to afford an orange-yellow solid (769.2 mg, 75%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 83:17, mp: 237–238 °C (lit <ce:cross-ref refid="bib30" id="crosref0365">[30]</ce:cross-ref> 238 °C).</ce:para>
                     <ce:para id="p0205" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((4-Bromophenyl)imino)indolin-2-one (3)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 4-bromoaniline (292.3 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 10 min at 100 °C. The final product was obtained without further purification as an orange solid (433.5 mg, 85%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 77:23, mp: 241–242 °C (lit <ce:cross-ref refid="bib17" id="crosref0370">[17]</ce:cross-ref> 242 °C).</ce:para>
                     <ce:para id="p0210" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(Phenylimino)indolin-2-one (4)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), aniline (158.2 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 10 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford a yellow solid (323.7 mg, 86%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 83:17, mp: 231–232 °C (lit <ce:cross-ref refid="bib31" id="crosref0375">[31]</ce:cross-ref> 232–234 °C).</ce:para>
                     <ce:para id="p0215" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((2-Methoxyphenyl)imino)indolin-2-one (5)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 2-methoxyaniline (209.2 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 10 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (116.3 mg, 27%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 83:17, mp: 179–180 °C (lit <ce:cross-ref refid="bib32" id="crosref0380">[32]</ce:cross-ref> 177–179 °C).</ce:para>
                     <ce:para id="p0220" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((2-(Trifluoromethyl)phenyl)imino)indolin-2-one (6)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 2-trifluoromethylaniline (273.7 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 20 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (262.3 mg, 53%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 62:38, mp: 144–145 °C (lit <ce:cross-ref refid="bib33" id="crosref0385">[33]</ce:cross-ref> 144 °C).</ce:para>
                     <ce:para id="p0225" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((2-Chlorophenyl)imino)indolin-2-one (7)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 2-chloroaniline hydrochloride (278.6 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 12 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford a yellow solid (16.6 mg, 4%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 77:23, mp: 236–237 °C (lit <ce:cross-ref refid="bib34" id="crosref0390">[34]</ce:cross-ref> 238 °C).</ce:para>
                     <ce:para id="p0230" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((2-Fluorophenyl)imino)indolin-2-one (8)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 2-fluoroaniline (188.8 mg, 1.7 mmol) and MMT-K10 (34 mg). Reaction conditions: 6 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (246.5 mg, 60%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 67:33, mp: 198–199 °C (lit <ce:cross-ref refid="bib35" id="crosref0395">[35]</ce:cross-ref> 198–199 °C).</ce:para>
                     <ce:para id="p0235" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((3-Chlorophenyl)imino)indolin-2-one (9)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 3-chloroaniline hydrochloride (278.6 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 6 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (45.1 mg, 10%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 63:37, mp: 219–220 °C (lit <ce:cross-ref refid="bib35" id="crosref0400">[35]</ce:cross-ref> 221–223 °C).</ce:para>
                     <ce:para id="p0240" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((4-Fluorophenyl)imino)indolin-2-one (10)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 4-fluoroaniline (188.8 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 6 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford a yellow solid (289.5 mg, 71%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 67:33, mp: 216–217 °C (lit <ce:cross-ref refid="bib36" id="crosref0405">[36]</ce:cross-ref> 210–216 °C).</ce:para>
                     <ce:para id="p0245" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-4-((2-oxoindolin-3-ylidene)amino)benzonitrile (11)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 4-aminobenzonitrile (200.7 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 1:1) to afford an orange solid (236.9 mg, 56%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 64:36, mp: 257–258 °C (lit <ce:cross-ref refid="bib37" id="crosref0410">[37]</ce:cross-ref> 257–259 °C).</ce:para>
                     <ce:para id="p0250" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((4-Nitrophenyl)imino)indolin-2-one (12)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 4-nitroaniline (234.7 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (110.5 mg, 24%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 64:36, mp: 236–237 °C (lit <ce:cross-ref refid="bib35" id="crosref0415">[35]</ce:cross-ref> 231–236 °C).</ce:para>
                     <ce:para id="p0255" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((4-(Dimethylamino)phenyl)imino)indolin-2-one (13)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), <ce:italic>N′</ce:italic>,<ce:italic>N’</ce:italic>-dimethylbenzene-1,4-diamine (231.4 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (380.1 mg, 84%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 76:24, mp: 224 °C (lit <ce:cross-ref refid="bib38" id="crosref0420">[38]</ce:cross-ref> 220 °C, decom.).</ce:para>
                     <ce:para id="p0260" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((2,4-Dimethoxyphenyl)imino)indolin-2-one (14)</ce:bold> 
                        <ce:cross-ref refid="bib39" id="crosref0425">[39]</ce:cross-ref>: Reagents: isatin (250 mg, 1.7 mmol), 2,4-dimethoxyaniline (260.3 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 6 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 3:2) to afford an orange-red solid (223.2 mg, 47%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 83:17, mp: 216–217 °C.</ce:para>
                     <ce:para id="p0265" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-((3,4-Dimethoxyphenyl)imino)indolin-2-one (15)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 3,4-dimethoxyaniline (260.3 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (1 mL). Reaction conditions: 6 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 4:1) to afford an orange-red solid (312.7 mg, 65%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 83:17, mp: 265–266 °C. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.91 (s, 1H), 7.31 (td, <ce:italic>J</ce:italic> = 7.7, 1.4 Hz, 1H), 7.03–6.99 (m, 1H), 6.86 (dt, <ce:italic>J</ce:italic> = 7.9, 0.8 Hz, 1H), 6.74 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 6.70–6.64 (m, 2H), 6.51 (dd, <ce:italic>J</ce:italic> = 8.4, 2.3 Hz, 1H), 3.76 (s, 3H), 3.68 (s, 3H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 164.4, 155.2, 150.2, 147.4, 147.1, 144.1, 134.9, 125.8, 122.4, 116.4, 113.1, 112.1, 109.9, 103.8, 56.4, 56.1. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.80 (s, 1H), 7.54–7.49 (m, 1H), 7.38 (td, <ce:italic>J</ce:italic> = 7.7, 1.3 Hz, 1H), 7.03–6.99 (m, 1H), 6.93–6.88 (m, 1H), 6.86 (dt, <ce:italic>J</ce:italic> = 7.9, 0.8 Hz, 1H), 6.81 (dt, <ce:italic>J</ce:italic> = 7.7, 0.8 Hz, 1H), 6.74 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 3.74 (s, 3H), 3.69 (s, 3H). MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 283 [M+H]. Anal. C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0270" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(2,2-Diphenylhydrazono)indolin-2-one (16)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 2,2-diphenylhydrazine hydrochloride (220.7 mg, 1.7 mmol), MMT-K10 (34 mg), triethylamine (171.9 mg, 1.7 mmol) and toluene (3 mL). Reaction conditions: 6 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford a green-yellow solid (394.8 mg, 74%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 95:5, mp: 246–248 °C (lit <ce:cross-ref refid="bib40" id="crosref0430">[40]</ce:cross-ref> 245–246 °C).</ce:para>
                     <ce:para id="p0275" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(Benzhydrylimino)indolin-2-one (17)</ce:bold> 
                        <ce:cross-ref refid="bib41" id="crosref0435">[41]</ce:cross-ref>: Reagents: isatin (250 mg, 1.7 mmol), diphenylmethanamine (311.3 mg, 1.7 mmol) and MMT-K10 (34 mg). Reaction conditions: 20 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange-yellow solid (255.1 mg, 48%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 35:65, mp: 173–174 °C.</ce:para>
                     <ce:para id="p0280" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(2-(4-Tolyl)hydrazono)indolin-2-one (18)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), 4-tolylhydrazine hydrochloride (269.5 mg, 1.7 mmol), triethylamine (171.9 mg, 1.7 mmol), MMT-K10 (34 mg) and toluene (3 mL). Reaction conditions: 10 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford an orange solid (104.1 mg, 24%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 14:86, mp: 224–225 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 12.71 (s, 1H), 10.97 (s, 1H), 7.50 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.23 (td, <ce:italic>J</ce:italic> = 7.7, 1.3 Hz, 1H), 7.18 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.04 (tdd, <ce:italic>J</ce:italic> = 7.6, 1.6, 0.9 Hz, 1H), 6.95–6.88 (m, 1H), 2.24 (s, 3H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 163.9, 140.9, 140.2, 132.7, 130.6, 128.9, 127.6, 122.5, 121.9, 119.1, 114.7, 111.1, 21.1. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 252 [M + 1]. Anal. C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0285" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(Piperidin-1-ylimino)indolin-2-one (19)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), piperidin-1-amine (170.2 mg, 1.7 mmol) and MMT-K10 (34 mg). Reaction conditions: 10 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 4:1) to afford an orange solid (335.0 mg, 86%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 46:54, mp: 142–143 °C (lit <ce:cross-ref refid="bib40" id="crosref0440">[40]</ce:cross-ref> 141–142 °C).</ce:para>
                     <ce:para id="p0290" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(Morpholinoimino)indolin-2-one (20)</ce:bold>: Reagents: isatin (250 mg, 1.7 mmol), morpholin-4-amine (173.6 mg, 1.7 mmol) and MMT-K10 (34 mg). Reaction conditions: 10 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 4:1) to afford an orange solid (354.5 mg, 59%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 88:12, mp: 184–186 °C (lit <ce:cross-ref refid="bib40" id="crosref0445">[40]</ce:cross-ref> 186–188 °C).</ce:para>
                     <ce:para id="p0295" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-3-(2-Benzyl-2-phenylhydrazono)indolin-2-one (21):</ce:bold> Reagents: isatin (350 mg, 2.4 mmol), 1-benzyl-1-phenylhydrazine hydrochloride (558.4 mg, 2.37 mmol), MMT-K10 (47.6 mg), triethylamine (239.8 mg, 2.37 mmol) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The crude product was purified by column chromatography (dichloromethane/methanol 30:1) to afford an orange solid (29.2 mg, 4%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 56:44, mp: 157–158 °C. Isomer <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.75 (s, 1H), 10.66 (s, 1H), 7.61–7.47 (m, 4H), 7.40–7.32 (m, 1H), 7.33–6.96 (m, 18H), 6.91 (dd, <ce:italic>J</ce:italic> = 7.9, 0.8 Hz, 1H), 6.83–6.77 (m, 2H), 6.61 (td, <ce:italic>J</ce:italic> = 7.8, 1.1 Hz, 1H), 6.27 (s, 2H), 6.26–6.20 (m, 1H), 5.23 (s, 2H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 166.1, 159.2, 147.5, 147.2, 143.8, 140.2, 139.0, 138.3, 137.5, 131.2, 129.8, 129.1, 128.8, 128.2, 128.0, 127.5, 127.1, 126.2, 125.7, 125.4, 124.7, 124.3, 123.4, 122.2, 121.6, 120.8, 120.0, 118.1, 116.4, 112.9, 110.7, 110.2, 63.6, 58.5. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 328 [M+H]. Anal. C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0300" view="all">
                        <ce:bold>(<ce:italic>E/Z</ce:italic>)-1-Benzyl-3-((4-fluorophenyl)imino)indolin-2-one (30)</ce:bold> 
                        <ce:cross-ref refid="bib42" id="crosref0450">[42]</ce:cross-ref>: Reagents: 1-benzylindoline-2,3-dione (200 mg, 0.8 mmol), 4-fluoroaniline (93.7 mg, 0.8 mmol), MMT-K10 (27 mg) and toluene (1 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 10:1) to afford an orange solid (243.6 mg, 88%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 77:23, mp: 200–201 °C.</ce:para>
                     <ce:para id="p0305" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>/Z)-3-((4-Methoxyphenyl)imino)-1-phenylindolin-2-one (31)</ce:bold> 
                        <ce:cross-ref refid="bib43" id="crosref0455">[43]</ce:cross-ref>: Reagents: 1-benzylindoline-2,3-dione (100 mg, 0.4 mmol), 4-methoxyaniline (527 mg, 0.4 mmol), MMT-K10 (13 mg) and toluene (5 mL). Reaction conditions: 1 h at 100 °C. The crude product was purified by column chromatography (dichloromethane) to afford an orange solid (103 mg, 72%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 80:20, mp: 153–154 °C.</ce:para>
                     <ce:para id="p0310" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>)-3-((4-Bromophenyl)imino)-1-methylindolin-2-one (32)</ce:bold>: Reagents: 1-methylindoline-2,3-dione (205 mg, 1.3 mmol), 4-bromoaniline (218 mg, 1.3 mmol), MMT-K10 (26 mg) and toluene (5 mL). Reaction conditions: 90 min at 100 °C. The crude product was purified by column chromatography (chloroform) to afford an orange solid (196 mg, 49%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 76:24, mp: 148–149 °C (lit <ce:cross-ref refid="bib44" id="crosref0460">[44]</ce:cross-ref> 148 °C).</ce:para>
                     <ce:para id="p0315" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-5-Chloro-3-(2,2-diphenylhydrazono)indolin-2-one (33)</ce:bold>: Reagents: 5-chloroisatin (250 mg, 1.4 mmol), 2,2-diphenylhydrazine hydrochloride (254.0 mg, 1.4 mmol), triethylamine (139.0 mg, 1.4 mmol), MMT-K10 (27 mg) and toluene (6 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford a yellow solid (284.1 mg, 59%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 85:15, mp: 305–306 °C (lit <ce:cross-ref refid="bib40" id="crosref0465">[40]</ce:cross-ref> 305–306 °C).</ce:para>
                     <ce:para id="p0320" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-5-Fluoro-3-(2,2-diphenylhydrazono)indolin-2-one (34)</ce:bold>: Reagents: 5-fluoroisatin (250 mg, 1.5 mmol), 2,2-diphenylhydrazine hydrochloride (279.0 mg, 1.5 mmol), triethylamine (153.0 mg, 1.5 mmol), MMT-K10 (30 mg) and toluene (5 mL). Reaction conditions: 1 h at 100 °C. The crude product was purified by column chromatography (dichloromethane) to afford a brown solid (138 mg, 27%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 96:4, mp: 228–229 °C. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.65 (s, 1H), 7.49 (m, 4H), 7.34 (m, 6H), 6.94 (ddd, <ce:italic>J</ce:italic> = 9.1, 8.5, 2.6 Hz, 1H), 6.73 (dd, <ce:italic>J</ce:italic> = 8.5, 4.7 Hz, 1H), 4.86 (dd, <ce:italic>J</ce:italic> = 10.5, 2.6 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 166.6, 157.37 (d, <ce:italic>J</ce:italic> = 234.0 Hz), 146.0, 139.9 (d, <ce:italic>J</ce:italic> = 1.5 Hz), 131.3, 130.3, 127.2, 123.9, 117.1 (d, <ce:italic>J</ce:italic> = 8.8 Hz), 116.8 (d, <ce:italic>J</ce:italic> = 23.7 Hz), 112.7 (d, <ce:italic>J</ce:italic> = 27.8 Hz), 111.1 (d, <ce:italic>J</ce:italic> = 8.1 Hz). MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 332 [M + 1]. Anal. C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>FN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0325" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-7-Chloro-3-(2,2-diphenylhydrazono)indolin-2-one (35)</ce:bold>: Reagents: 7-chloroisatin (250 mg, 1.4 mmol), 2,2-diphenylhydrazine hydrochloride (254.0 mg, 1.4 mmol), triethylamine (139.0 mg, 1.4 mmol), MMT-K10 (27 mg) and toluene (2 mL). Reaction conditions: 1 h at 100 °C. The crude product was purified by IsoleraOne (water/acetonitrile 4:1) to afford a yellow solid (344 mg, 72%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 92:8, mp: 208–209 °C. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 11.05 (s, 1H), 7.46 (m, 4H), 7.32 (m, 6H), 7.15 (dd, <ce:italic>J</ce:italic> = 8.2, 0.9 Hz, 1H), 6.41 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 5.23 (dd, <ce:italic>J</ce:italic> = 7.9, 0.9 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 166.5, 145.9, 141.0, 131.9, 130.3, 129.8, 127.1, 124.0, 123.8, 122.8, 122.2, 118.3. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 350 [M + 3H], 348 [M+H]. Anal. C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0330" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>)-5-Bromo-3-(2,2-diphenylhydrazono)indolin-2-one (36)</ce:bold>: Reagents: 5-bromoisatin (500 mg, 2.2 mmol), 2,2-diphenylhydrazine hydrochloride (485.5 mg, 2.2 mmol), MMT-K10 (44 mg), triethylamine (222.6 mg, 2.2 mmol) and toluene (3 mL). Reaction conditions: 10 min at 110 °C. The crude product was purified by IsoleraOne (water/acetonitrile 7:3) to afford a yellow solid (419.4 mg, 49%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 91:9, mp: 242–244 °C. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (500 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.75 (s, 1H), 7.48–7.42 (m, 4H), 7.36–7.31 (m, 6H), 7.23 (dd, <ce:italic>J</ce:italic> = 8.2, 2.1 Hz, 1H), 6.69 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 5.09 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C-NMR (125 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.9, 145.5, 142.3, 132.4, 130.1, 129.9, 127.8, 127.1, 123.7, 117.9, 113.0, 112.0. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (500 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.75 (s, 1H), 7.63–7.62 (m, 1H), 7.48 (m, 4H), 7.36–7.31 (m, 6H), 7.18 (m, 1H), 6.73 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H). MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 394 [M + 3H], 392 [M+H]. Anal. C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0335" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>)-3-(2,2-Diphenylhydrazono)-5-(trifluoromethoxy)indolin-2-one (37)</ce:bold>: Reagents: 5-trifluoromethoxyisatin (500 mg, 2.2 mmol), 2,2-diphenylhydrazine hydrochloride (485.5 mg, 2.2 mmol), MMT-K10 (44 mg), triethylamine (222.6 mg, 2.2 mmol) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The crude product was purified by column chromatography (dichloromethane/methanol 40:1) to afford a yellow solid (48 mg, 8%), mp: 230–231 °C. <ce:sup loc="pre">1</ce:sup>H-NMR (300 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>):δ 10.82 (s, 1H), 7.48–7.33 (m, 10H), 7.13–7.09 (m, 1H), 6.83 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1 H), 4.99 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H). <ce:sup loc="post">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>):δ 165.8, 145.2, 141.9, 129.9, 129.6, 123.2, 123.0, 118.6, 116.4, 110.5. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 398 [M+H]. Anal. C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">14</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0340" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>)-3-(2,2-Diphenylhydrazono)-5-methoxyindolin-2-one (38)</ce:bold>: Reagents: 5-methoxyisatin (500 mg, 2.8 mmol), 2,2-diphenylhydrazine hydrochloride (622.4 mg, 2.8 mmol), MMT-K10 (56.4 mg), triethylamine (284.5 mg, 2.8 mmol) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The crude product was purified by column chromatography (dichloromethane/methanol 40:1) to afford a yellow solid (20 mg, 6%), mp: 203–204 °C. <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.45 (s, 1H), 7.46–7.41 (m, 4H), 7.30–7.24 (m, 6H), 6.70 (dd, <ce:italic>J</ce:italic> = 8.5, 2.4 Hz, 1H), 6.60 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 5.27 (d, <ce:italic>J</ce:italic> = 2.4 Hz, 1H), 3.30 (s, 3H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 166.4, 154.4, 146.5, 137.7, 135.4, 130.3, 130.2, 123.6, 56.2.MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 344 [M+H]. Anal. C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0345" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-5-Chloro-3-(piperidin-1-ylimino)indolin-2-one (39)</ce:bold>: Reagents: 5-chloroisatin (250 mg, 1.4 mmol), piperidin-1-amine (137.0 mg, 1.4 mmol), MMT-K10 (27 mg) and toluene (5 mL). Reaction conditions: 30 min at 100 °C. The final product was obtained without further purification as a yellow solid (327 mg, 91%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 18:82, mp: 193–194 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.63 (s, 1H), 7.18 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.04 (dd, <ce:italic>J</ce:italic> = 8.2, 2.2 Hz, 1H), 6.73 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 4.08–3.95 (m, 4H), 1.73–1.54 (m, 6H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.1, 137.5, 130.4, 126.0, 125.8, 121.4, 117.6, 111.0, 58.6, 26.7, 23.8. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.72 (s, 1H), 7.31 (dd, <ce:italic>J</ce:italic> = 8.3, 2.1 Hz, 1H), 7.16 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.86 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H), 3.30–3.25 (m, 4H), 1.73–1.54 (m, 6H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.7, 142.2, 137.3, 128.2, 126.1, 124.9, 117.5, 112.4, 56.8, 25.7, 23.8. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 266 [M + 3H], 264 [M+H]. Anal. C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">14</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0350" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-5-Fluoro-3-(piperidin-1-ylimino)indolin-2-one (40)</ce:bold>: Reagents: 5-fluoroisatin (250 mg, 1.5 mmol), piperidin-1-amine (152.0 mg, 1.5 mmol), MMT-K10 (30 mg) and toluene (5 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by column chromatography (dichloromethane/methanol 150:1) to afford a yellow solid (311.6 mg, 83%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 30:70, mp: 169–170 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.55 (s, 1H), 7.01 (ddd, <ce:italic>J</ce:italic> = 8.9, 6.7, 2.7 Hz, 1.5H), 6.87 (m, 1.5H), 6.73 (dd, <ce:italic>J</ce:italic> = 8.4, 4.4 Hz, 1H), 4.04 (m, 4H), 1.77–1.48 (m, 9H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.4, 158.6 (d, <ce:italic>J</ce:italic> = 234.4 Hz), 135.0 (d, <ce:italic>J</ce:italic> = 1.3 Hz), 127.8 (d, <ce:italic>J</ce:italic> = 8.8 Hz), 122.4, 112.8 (d, <ce:italic>J</ce:italic> = 24.0 Hz), 110.3 (d, <ce:italic>J</ce:italic> = 8.2 Hz), 105.0 (d, <ce:italic>J</ce:italic> = 25.4 Hz), 58.5, 26.6, 23.8. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.64 (s, 0.5H), 7.15 (ddd, <ce:italic>J</ce:italic> = 9.4, 8.5, 2.6 Hz, 0.5H), 7.01 (ddd, <ce:italic>J</ce:italic> = 8.9, 6.7, 2.7 Hz, 1.5H), 6.87 (m, 1.5H), 3.30 (m, 2H), 1.77–1.48 (m, 9H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 166.0, 158.2 (d, <ce:italic>J</ce:italic> = 235.8 Hz), 139.9, 138.2, 117.2 (d, <ce:italic>J</ce:italic> = 23.5 Hz), 116.8 (d, <ce:italic>J</ce:italic> = 8.3 Hz), 112.4 (d, <ce:italic>J</ce:italic> = 26.1 Hz), 111.7, 56.8, 25.7, 23.9. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 248 [M+H]. Anal. C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">14</ce:inf>FN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0355" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-7-Chloro-3-(piperidin-1-ylimino)indolin-2-one (41)</ce:bold>: Reagents: 7-chloroisatin (250 mg, 1.4 mmol), piperidin-1-amine (137 mg, 1.4 mmol), MMT-K10 (27 mg) and toluene (5 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by column chromatography (dichloromethane/methanol 100:1) to afford a yellow solid (171.6 mg, 47%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 25:75, mp: 151–152 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.93 (s, 1H), 7.19 (ddd, <ce:italic>J</ce:italic> = 7.6, 4.5, 1.0 Hz, 1H), 7.09 (dd, <ce:italic>J</ce:italic> = 8.1, 1.0 Hz, 1H), 6.88 (ddd, <ce:italic>J</ce:italic> = 8.1, 7.5, 0.5 Hz, 1H), 4.82–3.77 (m, 4H), 1.75–1.53 (m, 6H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.0, 135.9, 130.5, 128.1, 126.2, 122.6, 116.7, 114.0, 58.6, 26.7, 23.7. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 11.02 (s, 1H), 7.33 (dd, <ce:italic>J</ce:italic> = 8.2, 0.9 Hz, 1H), 7.19 (ddd, <ce:italic>J</ce:italic> = 7.6, 4.5, 1.0 Hz, 1H), 7.09–7.00 (m, 1H), 3.31–3.25 (m, 1H), 1.75–1.53 (m, 9H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.9, 140.8, 137.3, 124.1, 123.5, 122.1, 118.1, 115.2, 56.8, 25.7, 23.9. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 266 [M + 3H], 264 [M+H]. Anal C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">14</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0360" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-5-Bromo-3-(piperidin-1-yimino)indolin-2-one (42):</ce:bold> Reagents: 5-Bromoisatin (500 mg, 2.2 mmol), piperidin-1-amine (220.4 mg, 2.2 mmol), MMT-K10 (44 mg), triethylamine (222.6 mg, 2.2 mmol) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The crude product was purified by column chromatography (dichloromethane/methanol 30:1) to afford a yellow solid (42.2 mg, 6%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 23:77, mp: 168–170 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.63 (s, 1H), 7.30 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.16 (dd, <ce:italic>J</ce:italic> = 8.2, 2.0 Hz, 1H), 6.68 (d, <ce:italic>J</ce:italic> = 8.2, 0.5 Hz, 1 H), 4.08 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 4H), 1.72–1.55 (m, 6H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 158.9, 142.6, 137.6, 128,8, 120.4, 113.5, 111.5, 58.6, 26.7, 23.8. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.73 (s, 1H), 7.45 (dd, <ce:italic>J</ce:italic> = 8.3, 2.1 Hz, 1H), 7.30 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.82 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 3.29 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H), 1.72–1.55 (m, 9H).<ce:sup loc="post">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.5, 121.2, 56.8, 25.7. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 310 [M + 3H], 308 [M+H]. Anal. C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">14</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0365" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-5-Methoxy-3-(piperidin-1-ylimino)indolin-2-one (43):</ce:bold> Reagents: 5-Methoxyisatin (350.0 mg, 2.0 mmol), piperidin-1-amine (198.3, 2.0 mmol) y MMT-K10 (39.6 mg) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The final product was obtained without further purification as an orange solid (260 mg, 51%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 40:60, mp: 173–175 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.33 (s, 1H), 6.93–6.84 (m, 1H), 6.80 (dd, <ce:italic>J</ce:italic> = 1.6, 0.9 Hz, 1H), 6.65–6.60 (m, 1H), 3.91–3.89 (m, 4H), 3.67 (s, 3H), 1.83–1.38 (m, 6H).<ce:sup loc="post">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.4, 155.2, 141.6, 133.0, 117.1, 112.3, 111.5, 103.9, 58.4, 56.0, 26.6, 24.1. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.43 (s, 1H), 6.93–6.84 (m, 1H), 6.78 (dd, <ce:italic>J</ce:italic> = 8.2, 0.7 Hz, 1 H), 6.65–6.60 (m, 1H), 3.71 (s, 3H), 3.20–3.15 (m, 4H), 1.83–1.38 (m, 6H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.9, 155.1, 126.9, 110.40, 56.4, 56.2, 23.9, 23.8. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 260 [M + 1]. Anal. C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0370" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-5-Chloro-3-(morpholinoimino)indolin-2-one (44)</ce:bold>: Reagents: 5-chloroisatin (250 mg, 1.4 mmol), morpholin-4-amine (141 mg, 1.4 mmol), MMT-K10 (27 mg) and toluene (5 mL). Reaction conditions: 1 h at 100 °C. The crude product was purified by column chromatography (dichloromethane/methanol 100:1) to afford a yellow solid (280.8 mg, 77%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 26:74, mp: 192–193 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.79 (s, 1H), 7.25 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.14 (dd, <ce:italic>J</ce:italic> = 8.2, 2.2 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 4.04 (dd, <ce:italic>J</ce:italic> = 6.2, 3.6 Hz, 4H), 3.80 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.1, 138.1, 127.3, 127.0, 126.0, 124.5, 118.3, 111.3, 66.6, 57.7. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.84 (s, 1H), 7.39 (dd, <ce:italic>J</ce:italic> = 8.4, 2.1 Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.90 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H), 3.80 (m, 4H), 3.29 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.3, 143.0, 141.1, 131.5, 126.3, 125.8, 117.1, 112.6, 66.1, 56.0. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 268 [M + 3H], 266 [M+H]. Anal. C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">12</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0375" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-5-Fluoro-3-(morpholinoimino)indolin-2-one (45)</ce:bold>: Reagents: 5-fluoroisatin (250 mg, 1.5 mmol), morpholin-4-amine (155 mg, 1.5 mmol), MMT-K10 (30 mg) and toluene (5 mL). Reaction conditions: 30 min at 100 °C. The crude product was purified by column chromatography (dichloromethane/methanol 100:1) to afford a yellow solid (149.2 mg, 40%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 30:70, mp: 191–192 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.66 (s, 1H), 7.01 (dd, <ce:italic>J</ce:italic> = 8.7, 2.7 Hz, 1H), 6.90 (ddd, <ce:italic>J</ce:italic> = 9.8, 8.4, 2.7 Hz, 1H), 6.76–6.70 (m, 1H), 4.03–3.96 (m, 4H), 3.77–3.71 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.4, 158.7 (d, <ce:italic>J</ce:italic> = 235.1 Hz), 135.8 (d, <ce:italic>J</ce:italic> = 1.1 Hz), 126.9 (d, <ce:italic>J</ce:italic> = 9.0 Hz), 125.7 (d, <ce:italic>J</ce:italic> = 3.3 Hz), 113.9 (d, <ce:italic>J</ce:italic> = 24.0 Hz), 110.7 (d, <ce:italic>J</ce:italic> = 8.4 Hz), 105.7 (d, <ce:italic>J</ce:italic> = 25.2 Hz), 66.6, 57.6. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.70 (s, 1H), 7.17 (ddd, <ce:italic>J</ce:italic> = 9.5, 8.5, 2.6 Hz, 1H), 7.10 (dd, <ce:italic>J</ce:italic> = 8.8, 2.6 Hz, 1H), 6.85 (dd, <ce:italic>J</ce:italic> = 8.6, 4.5 Hz, 1H), 3.82–3.77 (m, 4H), 3.27–3.21 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.6, 158.2 (d, <ce:italic>J</ce:italic> = 236.8 Hz), 141.9 (d, <ce:italic>J</ce:italic> = 2.5 Hz), 140.6 (d, <ce:italic>J</ce:italic> = 1.6 Hz), 118.4 (d, <ce:italic>J</ce:italic> = 23.6 Hz), 116.3 (d, <ce:italic>J</ce:italic> = 8.6 Hz), 113.5 (d, <ce:italic>J</ce:italic> = 25.8 Hz), 112.0 (d, <ce:italic>J</ce:italic> = 8.1 Hz), 66.1, 56.0. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 250 [M+H]. Anal. C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">12</ce:inf>FN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0380" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-7-Chloro-3-(morpholinoimino)indolin-2-one (46)</ce:bold>: Reagents: 7-chloroisatin (250 mg, 1.4 mmol), morpholin-4-amine (141 mg, 1.4 mmol), MMT-K10 (27 mg) and toluene (5 mL). Reaction conditions: 1 h at 100 °C. The crude product was purified by column chromatography (dichloromethane/methanol 100:1) to afford a yellow solid (204.6 mg, 56%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 26:74, mp: 178–179 °C (lit <ce:cross-ref refid="bib40" id="crosref0470">[40]</ce:cross-ref> 180–181 °C).</ce:para>
                     <ce:para id="p0385" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-5-Bromo-3-(morpholinoimino)indolin-2-one (47)</ce:bold>: Reagents: 5-bromoisatin (500 mg, 2.2 mmol), morpholin-4-amine (224.7 mg, 2.2 mmol), MMT-K10 (44 mg) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The crude product was purified by column chromatography (dichloromethane/methanol 30:1) to afford a yellow solid (28 mg, 10%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 25:75, mp: 191–193 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.78 (s, 1H), 7.35 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 7.24 (dd, <ce:italic>J</ce:italic> = 8.2, 2.0 Hz, 1H), 6.73 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 4.02 (t, <ce:italic>J</ce:italic> = 4.9 Hz, 4H), 3.85–3.71 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 158.9, 141.1, 138.4, 129.8, 124.3, 121.0, 113.7, 111.9, 66.7, 57.7. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.82 (s, 1H), 7.49 (dd, <ce:italic>J</ce:italic> = 8.3, 1.9 Hz, 1H), 7.39 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.84 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 3.85–3.71 (m, 4H), 3.20 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.2, 143.4, 134.4, 127.8, 114.0, 66.1, 56.0. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 313 [M + 3H], 310 [M+H]. Anal. C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">12</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0390" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-5-(Trifluoromethoxy)-3-morpholinoimino)indolin-2-one (48):</ce:bold> Reagents: 5-trifluoromethoxyisatin (350.0 mg, 1.5 mmol), morpholin-4-amine (268.4, 1.5 mmol), MMT-K10 (30.2 mg) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The final product was obtained without further purification as a yellow solid (392.1 mg, 83%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 12:88, mp: 153–154 °C. Isomer <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.81 (s, 1H), 7.13 (dd, <ce:italic>J</ce:italic> = 2.5, 1.2 Hz, 1H), 7.10–7.02 (m, 1H), 6.80 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 4.05–3.95 (m, 4H), 3.78–3.73 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.3, 143.7, 138.2, 126.9, 124.5, 121.0 (q, <ce:italic>J</ce:italic> = 254 Hz), 120.4, 112.6, 110.7, 66.6, 57.3. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 316 [M+H]. Anal. C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">12</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0395" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-5-Methoxy-3-(morpholinoimino)indolin-2-one (49):</ce:bold> Reagents: 5-methoxyisatin (350.0 mg, 2.0 mmol), morpholin-4-amine (202.2 mg, 2.0 mmol), MMT-K10 (39.6 mg) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The final product was obtained without further purification as an orange solid (167 mg, 32%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 30:70, mp: 168–170 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (500 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.49 (s, 1H), 6.95–6.94 (m, 1H), 6.71 (dd, <ce:italic>J</ce:italic> = 8.4, 2.4 Hz, 1H), 6.68 (dd, <ce:italic>J</ce:italic> = 8.4, 0.7 Hz, 1H), 3.96–3.85 (m, 4H), 3.79–3.73 (m, 4H), 3.69 (s, 3H). <ce:sup loc="pre">13</ce:sup>C-NMR (125 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 159.3, 155.3, 144.1138.3, 126.0, 112.7, 110.3, 104.5, 66.5, 57.3, 56.1. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (500 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.52 (s, 1H), 6.93 (d, <ce:italic>J</ce:italic> = 2.6 Hz, 1H), 6.85 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.80 (dd, <ce:italic>J</ce:italic> = 7.9, 0.9 Hz, 1H), 3.84–3.78 (m, 4H), 3.70 (s, 3H), 3.21–3.15 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (125 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.1, 155.2, 133.9, 128.3, 118.1, 117.9, 111.7, 66.1, 56.2, 55.8. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 262 [M+H]. Anal. C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0400" view="all">
                        <ce:bold>(<ce:italic>E,Z</ce:italic>)-5-Iodo-3-(morpholinoimino)indolin-2-one (50):</ce:bold> Reagents: 5-Iodoisatin (350.0 mg, 1.3 mmol), morpholin-4-amine (226.7 mg, 1.3 mmol), MMT-K10 (25.6 mg) and toluene (3 mL). Reaction conditions: 40 min at 110 °C. The final product was obtained without further purification as a yellow solid (246 mg, 72%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 30:70, mp: 198–199 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (300 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.76 (s, 1H), 7.65–7.63 (dd, <ce:italic>J</ce:italic> = 8.2, 1.7 Hz, 1H), 7.42–7.40 (dd, <ce:italic>J</ce:italic> = 8.1, 1.8 Hz, 1H), 6.63 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 4.01–3.99 (m, 4H), 3.77–3.75 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 158.4, 141.2, 138.3, 134.9, 127.8, 126.1, 111.7, 84.0, 66.4, 57.5. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (300 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 10.76 (s, 1H), 7.65–7.63 (dd, <ce:italic>J</ce:italic> = 8.2, 1.7 Hz, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 1.7 Hz, 1H), 6.74 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 3.77–3.75 (m, 4H), 3.25–3.23 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 164.7, 143.6, 138.3, 133.9, 113.3, 85.02, 65.8, 55.8 MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 358 [M+H]. Anal. C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">12</ce:inf>IN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0405" view="all">
                        <ce:bold>
                           <ce:italic>Synthesis of N-substituted compounds 22–28</ce:italic>
                        </ce:bold>: For the synthesis of these compounds we followed the procedure described by Ottoni et al. <ce:cross-ref refid="bib19" id="crosref0475">[19]</ce:cross-ref> In our case, the crude was purified by column chromatography using chloroform as eluent.</ce:para>
                     <ce:para id="p0410" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(2,2-Diphenylhydrazono)-1-methylindolin-2-one (22)</ce:bold>: Reagents: (<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(2,2-diphenylhydrazono)indolin-2-one (100 mg, 0.3 mmol), dimethyl sulfate (50.2 mg, 0.4 mmol), KOH (22.3 mg, 0.4 mmol), ethanol (3 mL) and acetone (3 mL). Final product: orange solid (273.9 mg, 86%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 91:9, m.p: 193–194 °C. (lit. <ce:cross-ref refid="bib45" id="crosref0480">[45]</ce:cross-ref> 194–195 °C).</ce:para>
                     <ce:para id="p0415" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-1-Benzyl-3-(2,2-Diphenylhydrazono)indolin-2-one (23)</ce:bold>: Reagents: (<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(2,2-diphenylhydrazono)indolin-2-one (100 mg, 0.3 mmol), benzyl bromide (68.2 mg, 0.4 mmol), KOH (22.3 mg, 0.4 mmol), ethanol (3 mL) and acetone (3 mL). Final product: orange solid (110.5 mg, 96%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 80:20, m.p: 177–178 °C. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.52–7.40 (m, 4H), 7.35–7.26 (m, 9H), 7.26–7.16 (m, 2H), 7.06 (td, <ce:italic>J</ce:italic> = 7.8, 1.2 Hz, 1H), 6.91–6.81 (m, 1H), 6.42 (td, <ce:italic>J</ce:italic> = 7.7, 1.1 Hz, 1H), 5.34 (ddd, <ce:italic>J</ce:italic> = 7.9, 1.2, 0.5 Hz, 1H), 4.94 (s, 2H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 165.4, 146.6, 146.2, 143.7, 137.1, 132.3, 130.7, 129.8, 129.2, 128.0, 127.8, 126.9, 125.6, 122.8, 121.9, 109.8, 43.3. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 404 [M+H]. Anal. C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0420" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-1-Methyl-3-(piperidin-1-ylimino)indolin-2-one (24)</ce:bold>: Reagents: (<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(piperidin-1-ylimino)indolin-2-one (250 mg, 1.1 mmol), dimethyl sulfate (137 mg, 1.1 mmol), KOH (76 mg, 1.4 mmol), ethanol (10 mL) and acetone (10 mL). Final product: orange oil (78 mg, 29%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 49:61. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.31 (ddd, <ce:italic>J</ce:italic> = 7.5, 1.2, 0.6 Hz, 1H), 7.17 (td, <ce:italic>J</ce:italic> = 7.7, 1.2 Hz, 1H), 6.96 (m, 2H), 4.00 (t, 4H), 3.18 (s, 3H), 1,72 (m, 4H), 1,61 (m, 2H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 157.4, 140.3, 139.7, 127.1, 124.9, 122.1, 118.1, 108.6, 58.3, 26.6, 25.6, 23.9. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.39 (td, <ce:italic>J</ce:italic> = 7.7, 1.2 Hz, 1H), 7.35 (ddd, <ce:italic>J</ce:italic> = 7.7, 1.3, 0.6 Hz, 1H), 7.13 (td, <ce:italic>J</ce:italic> = 7.6, 1.0 Hz, 1H), 7.07 (m, 1H), 3.25 (m, 4H), 3.17 (s, 3H), 1.72 (m, 4H), 1,61 (m, 2H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 164.5, 145.0, 139.7, 131.5, 125.7, 123.0, 122.9, 109.7, 56.7, 26.6, 26.5, 23.9. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 244 [M+H]. Anal. C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0425" view="all">
                        <ce:bold>(<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-1-Benzyl-3-(piperidin-1-ylimino)indolin-2-one (25)</ce:bold>: Reagents: (<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(piperidin-1-ylimino)indolin-2-one (250 mg, 1.1 mmol), benzyl bromide (186 mg, 1.1 mmol), KOH (78 mg, 1.4 mmol), ethanol (10 mL) and acetone (10 mL). Final product: yellow solid (85 mg, 24%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 33:67, m.p: 127–128 °C. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.31 (m, 6H), 7.09 (td, <ce:italic>J</ce:italic> = 7.8, 1.2 Hz, 1H), 6,97 (m, 1H), 6.88 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 4.95 (s, 2H), 4.06–4.03 (m, 4H), 1.78–1.70 (m, 4H), 1.62–1.58 (m, 2H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 157.3, 139.2, 138.4, 131.1, 128.1, 127.9, 126.9, 125.1, 123.1, 118.2, 109.2, 58.4, 43.3, 26.6, 23.9. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.31 (m, 7H), 7.09 (cd, <ce:italic>J</ce:italic> = 7.8, 1.2 Hz, 1H), 6,97 (m, 1H), 4.95 (s, 2H), 3.31 (d, <ce:italic>J</ce:italic> = 5.7 Hz, 4H), 1.78–1.70 (m, 4H), 1.62–1.58 (m, 2H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 164.6, 143.7, 137.2, 129.8, 129.6, 129.3, 125.7, 125.5, 122.2, 115.8, 110.2, 56.7, 43.2, 25.7, 23.8. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 320 [M+H]. Anal. C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">3</ce:inf>O (C, H, N, O).</ce:para>
                     <ce:para id="p0430" view="all">
                        <ce:bold>(<ce:italic>E/Z</ce:italic>)-1-Methyl-3-(morpholinoimino)indolin-2-one (26)</ce:bold>: Reagents: (<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(morpholinoimino)indolin-2-one (168 mg, 0.7 mmol), dimethyl sulfate (92 mg, 0.7 mmol), KOH (51 mg, 0.9 mmol), ethanol (10 mL) and acetone (10 mL). Final product: yellow solid (84.3 mg, 47%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 59:41, m.p: 117–118 °C (lit <ce:cross-ref refid="bib40" id="crosref0485">[40]</ce:cross-ref> 116–118 °C).</ce:para>
                     <ce:para id="p0435" view="all">
                        <ce:bold>(<ce:italic>E/Z</ce:italic>)-1-Benzyl-3-(morpholinoimino)indolin-2-ona (27)</ce:bold>: Reagents: (<ce:italic>E</ce:italic>,<ce:italic>Z</ce:italic>)-3-(morpholinoimino)indolin-2-one (200 mg, 0.9 mmol), benzyl bromide (148 mg, 0.9 mmol), KOH (63 mg, 1.12 mmol), ethanol (10 mL) and acetone (10 mL). Final product: orange oil (90 mg, 32%), ratio <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>: 45:55. Isomer <ce:italic>Z</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.37 (m, 1H), 7.35–7.32 (m, 5H), 7.13 (td, <ce:italic>J</ce:italic> = 7.6, 1.1 Hz, 1H), 6.99 (m, 1H), 6.92 (dt, <ce:italic>J</ce:italic> = 7.9, 0.8 Hz, 1H), 4.95 (s, 2H), 4.01 (m, 4H), 3.82 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 156.7, 141.1, 139.5, 136.9, 128.7, 127.5, 127.4, 127.3, 123.7, 122.8, 118.3, 108.9, 66.0, 56.9, 42.8. Isomer <ce:italic>E</ce:italic>: <ce:sup loc="pre">1</ce:sup>H-NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 7.44 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.37 (m, 1H), 7.32 (m, 5H), 7.13 (dt, <ce:italic>J</ce:italic> = 7.6, 1.1 Hz, 1H), 6.99 (m, 1H), 4.95 (s, 2H), 3.82 (m, 4H), 3.28 (m, 4H). <ce:sup loc="pre">13</ce:sup>C-NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf>): δ 163.7, 143.9, 141.4, 136.4, 131.5, 128.8, 127.4, 126.2, 125.2, 122.0, 114.8, 109.8, 65.6, 55.3, 42.6. MS (ESI+): <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> 322 [M+H]. Anal. C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> (C, H, N, O).</ce:para>
                     <ce:para id="p0440" view="all">
                        <ce:bold>
                           <ce:italic>Synthesis of 28 and 29</ce:italic>.</ce:bold> The isatin derivative (1 eq) and NaH (1 eq) were dissolved in anhydrous DMF (20 mL), the mixture was stirred at room temperature during 2 h. After that, benzyl bromide (1 eq) was added and stirred until the reaction was finished. The solvent was removed under reduced pressure. Ethyl acetate (50 mL) was added and the organic layer was washed with a satured solution of NaCl (2 × 50 mL). After that, the organic phase was dried over magnesium sulfate and the solvent evaporated under reduced pressure. The crude was purified by column chromatography using chloroform as eluent.</ce:para>
                     <ce:para id="p0445" view="all">
                        <ce:bold>1-Benzylindolin-2,3-dione (28):</ce:bold> Reagents: isatin (1 g, 6.8 mmol), benzyl bromide (1.4 g, 8.2 mmol), NaH (196.8 mg, 8.2 mmoL) and DMF (20 mL). Reaction conditions: 1 h at room temperature. Final product: orange solid (1.32 g, 82%), m.p: 132–133 °C (lit. <ce:cross-ref refid="bib46" id="crosref0490">[46]</ce:cross-ref> 131–133 °C).</ce:para>
                     <ce:para id="p0450" view="all">
                        <ce:bold>1-Methylindolin-2,3-dione (29):</ce:bold> Reagents: isatin (1 g, 6.8 mmol), methyl iodide (1.2 mg, 8.2 mmol), NaH (196.8 mg, 8.2 mmoL) and DMF (20 mL). Reaction conditions: 16 h at room temperature. Final product: orange solid (571.1 g, 52%), m.p: 122–123 °C (lit. <ce:cross-ref refid="bib47" id="crosref0495">[47]</ce:cross-ref> 121.7–123.5 °C).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0085">Molecular modelling</ce:section-title>
                     <ce:para id="p0455" view="all">The human LRRK2 sequence was retrieved from Swiss-Prot <ce:cross-ref refid="bib48" id="crosref0500">[48]</ce:cross-ref> and aligned to template structure sequence using ClustalW <ce:cross-ref refid="bib49" id="crosref0505">[49]</ce:cross-ref>. The percentage of identity between the kinase domain of LRRK2 and the kinase domain of Janus Kinase 2 was 26.3%. Other kinases, for instance TIE2, showed higher percentage of identity. However, they were not used as we could not reproduce with them the same environment around the catalytic residues that has been reported in the literature <ce:cross-ref refid="bib24" id="crosref0510">[24]</ce:cross-ref>. Finally, the model using JAK2 as template was built using Swiss-Model <ce:cross-ref refid="bib50" id="crosref0515">[50]</ce:cross-ref>. The model has been visualized using Sybyl-X 2.0 <ce:cross-ref refid="bib51" id="crosref0520">[51]</ce:cross-ref> showing a RMS value between the model and the 3-D structure of the template of 3.12. Later on, the model was evaluated geometrically using the Ramachandran plot <ce:cross-ref refid="bib52" id="crosref0525">[52]</ce:cross-ref> and energetically with the server Verify3D <ce:cross-ref refid="bib53" id="crosref0530">[53]</ce:cross-ref>. The docking studies were carried out using the docking program Glide XP implemented in the Schrödinger suite program (Schrödinger, Inc., New York, NY). The inputs complexes to the docking studies were constructed employing the data about the binding site available <ce:cross-ref refid="bib24" id="crosref0535">[24]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0090">Biology</ce:section-title>
                     <ce:para id="p0460" view="all">
                        <ce:bold>
                           <ce:italic>In vitro LRRK2 and LRRK2 G2019S activity assay</ce:italic>
                        </ce:bold>. LRRK2 kinase activity was measured using Adapta<ce:sup loc="post">®</ce:sup> Screen technology from Life Technologies™ (Invitrogen) consisting of a fluorescent-based immunoassay for the detection of ADP. Kinase activity was evaluated following the Adapta assay validation protocols PV4873 and PV4881 for LRRK2 and LRRK2 G2019S respectively. Duplicate assay mixtures were set up each in a 10 μL volume containing 17 ng (8 nM) of recombinantly expressed, human LRRK2 protein (Cat. ♯PV4873), 200 μM LRRKtide (Cat. ♯PV5093), 25 mM Tris/7.5 mM HEPES pH 8.2, 5 mM MgCl<ce:inf loc="post">2</ce:inf>, 0.5 mM EGTA, 10 μM ATP, 0.01% NaN<ce:inf loc="post">3,</ce:inf> 0.005% Brij-35, 1% DMSO and compound of interest in a series of concentrations (e.g. for 10 point titrations, 3-fold serial dilutions are conducted starting from 100 μM concentration) in a 384 well microplate (Corning model 3674). Mutant LRRK2 G2019S inhibition was determined similarly except that due to the higher specific activity 0.5 ng (2.5 nM) of the LRRK2 G2019S mutant kinase (Cat. ♯ PV4881) is used in the assays. A series of controls were incubated on the same plate with: (i) kinase inactivated by EDTA, and (ii) mixtures containing incrementally increased ADP concentrations from 0 to 100 μM, and inversely decreased ATP concentrations from 100 to 0 μM, to establish a standard curve delimited by ADP concentrations corresponding to no conversion and complete conversion of ATP in the assay mixture. After 1 h incubation at ambient temperature, 5 μL of the Adapta<ce:sup loc="post">®</ce:sup> Assay Detection Mix (Cat. ♯ PV5099) was added, containing 30 mM EDTA to stop the kinase reaction, 6 nM of the Eu-labelled anti-ADP antibody (Cat.♯ (PV5097), and 18.9 nM of the AlexaFluor°-ADP conjugate (Cat.♯ PV5098). The plate was allowed to equilibrate at room temperature for at least 30 min before being read out in a fluorescence microplate reader to establish the ratio of emissions at 665 nm (ADP-tracer) and at 615 nm (Eu-antibody) as a measure of ADP concentration by virtue of Fluorescence Resonance Energy Transfer (FRET). The conversion in % of ATP into ADP by the kinase reaction in each well is determined from the ADP/ATP standard curve, and means are formed from each duplicate assay well. The resultant mean conversion ratios for the kinase assays containing increasing concentrations of inhibitor are fitted to a sigmoidal binding model (Graphpad), with the assay containing no inhibitor (<40% ATP conversion for linearity) taken as the 100% activity control (top), and the control assay with the kinase inhibited by excess EDTA as the 0% activity control (bottom). The IC<ce:inf loc="post">50</ce:inf> is determined by the intersection of the fitted curve with the 50% activity measure.</ce:para>
                     <ce:para id="p0465" view="all">
                        <ce:bold>
                           <ce:italic>In vitro Parallel artificial membrane permeability assay (PAMPA)-Blood brain barrier (BBB).</ce:italic>
                        </ce:bold> Prediction of the brain penetration was evaluated using a parallel artificial membrane permeability assay (PAMPA). Ten commercial drugs, phosphate buffer saline solution at pH 7.4 (PBS), ethanol and dodecane were purchased from Sigma, Acros organics, Merck, Aldrich and Fluka. The porcine polar brain lipid (PBL) (catalog no. 141101) was from Avanti Polar Lipids. The donor plate was a 96-well filtrate plate (Multiscreen<ce:sup loc="post">®</ce:sup> IP Sterile Plate PDVF membrane, pore size is 0.45 μM, catalog no. MAIPS4510) and the acceptor plate was an indented 96-well plate (Multiscreen<ce:sup loc="post">®</ce:sup>, catalog no. MAMCS9610) both from Millipore. Filter PDVF membrane units (diameter 30 mm, pore size 0.45 μm) from Symta were used to filter the samples. A 96-well plate UV reader (Thermoscientific, Multiskan spectrum) was used for the UV measurements. Test compounds [(3–5 mg of caffeine, enoxacine, hydrocortisone, desipramine, ofloxacine, piroxicam, testosterone), 12 mg of promazine and 25 mg of verapamile and atenolol] were dissolved in EtOH (1000 μL). 100 μL of this compound stock solution was taken and 1400 μL of EtOH and 3500 μL of PBS pH = 7.4 buffer were added to reach 30% of EtOH concentration in the experiment. These solutions were filtered. The acceptor 96-well microplate was filled with 180 μL of PBS/EtOH (70/30). The donor 96-well plate was coated with 4 μL of porcine brain lipid in dodecane (20 mg mL-1) and after 5 min, 180 μL of each compound solution was added. 1–2 mg of every compound to be determined their ability to pass the brain barrier were dissolved in 1500 μL of EtOH and 3500 μL of PBS pH = 7.4 buffer, filtered and then added to the donor 96-well plate. Then the donor plate was carefully put on the acceptor plate to form a “sandwich”, which was left undisturbed for 2 h and 30 min at 25 °C. During this time the compounds diffused from the donor plate through the brain lipid membrane into the acceptor plate. After incubation, the donor plate was removed. UV plate reader determined the concentration of compounds and commercial drugs in the acceptor and the donor wells. Every sample was analyzed at three to five wavelengths, in 3 wells and in two independent runs. Results are given as the mean [standard deviation (SD)] and the average of the two runs is reported. 10 quality control compounds (previously mentioned) of known BBB permeability were included in each experiment to validate the analysis set.</ce:para>
                     <ce:para id="p0470" view="all">
                        <ce:bold>
                           <ce:italic>Neurosphere cultures. Proliferation and differentiation assays</ce:italic>
                        </ce:bold>. All animal care and handling was carried out in accordance with European Union guidelines (directives 86/609/EEC and 2010/63/EU) and Spanish legislation (Law 32/2007 and RD 53/2013), and the protocols were approved by the Ethical Committee of the Consejo Superior de Investigaciones Cientificas (CSIC) and Comunidad de Madrid. All efforts were made to ameliorate the suffering of the animals and to reduce the number of animals used to a minimum.</ce:para>
                     <ce:para id="p0475" view="all">Neurosphere (NS) cultures were derived from the subventricular zone of 4 young adult (6 weeks old) C57BL/6 mice and induced to proliferate using established passaging methods to achieve optimal cellular expansion according to published protocols <ce:cross-ref refid="bib54" id="crosref0540">[54]</ce:cross-ref>. Briefly, mice were euthanized with CO<ce:inf loc="post">2</ce:inf>, brains were removed and the subventricular zone was dissected, cut up into pieces and digested using 0.7 mg/ml papain, 0.2 mg/ml cysteine and 0.2 mg/ml EDTA before it was gently disaggregated. The resulted cell suspension was plated into 8 wells of 12-well plates containing DMEM-F12 supplemented with insulin (10 mg/ml), apotransferrin, putrescine, progesterone, sodium selenite (N2), and B27. The cells were passaged by mechanical procedures and were maintained until passaged 3 for the first experiments, with alternative daily addition of both 10 ng/ml of fibroblast growth factor (FGF, Peprotech Cat No. 100-18B) and 2 ng/mL of epidermal growth factor (EGF, Peprotech Cat No. AF-100-15). Cell proliferation assays were performed on floating neurospheres in 96-well plates at a density of 5000 cells/cm<ce:sup loc="post">2</ce:sup>. LRRK2 inhibitors were diluted in DMSO at a concentration of 10 mM and then added to the dissociated cells to a final concentration of 5 μM and 0.1% DMSO was used as a control. Each treatment was repeated by triplicate and the cells were left to grow at 37 °C and 5% of CO<ce:inf loc="post">2</ce:inf> in an incubator for 3 days. On the third day, for the measurement of the size and number of the neurospheres, photographs were taken by bright field microscopy using an automatic platten, taken 6 pictures of different areas of each well with the 10X objective. The total number and area of neurospheres bigger than 400 μm <ce:cross-ref refid="bib2" id="crosref0545">[2]</ce:cross-ref> cell area was measured using a macro software for Image J, (NIH, Bethesda, MD) designed at the Cajal Institute. Quantitative analyses were carried out in three separate experiments, calculating the mean ± SEM and using a two-tailed Student's <ce:italic>t</ce:italic>-test to determine statistically relevant changes.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0095">Acknowledgements</ce:section-title>
               <ce:para id="p0480" view="all">Financial support from <ce:grant-sponsor id="gs1" sponsor-id="http://dx.doi.org/10.13039/501100003329" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">MINECO</ce:grant-sponsor> (grant no. <ce:grant-number refid="gs1">SAF2012-37979-C03-01</ce:grant-number> and <ce:grant-number refid="gs1">RTC-2015-3439-1</ce:grant-number> to A. M. and <ce:grant-number refid="gs1">BFU2014-57494-R</ce:grant-number> to A. V. M), <ce:grant-sponsor id="gs2" sponsor-id="http://dx.doi.org/10.13039/501100003176" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">MECD</ce:grant-sponsor> (<ce:grant-number refid="gs2">FPU13-003262</ce:grant-number> to J. Z. D. and <ce:grant-number refid="gs2">FPU15/01465</ce:grant-number> to V.S.P). Technical assistance of Maria Ciorraga is also acknowledged. A.M. and C.G are members of the “CIB Intramural Program “Molecular Machines for Better Life” (MACBET)”</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0100">Supplementary data</ce:section-title>
                  <ce:para id="p0485" view="all">The following is the supplementary data related to this article:</ce:para>
                  <ce:para id="p0490" view="all">Elemental analysis of new compounds (<ce:cross-ref refid="appsec2" id="crosref0550">Table S1</ce:cross-ref>); Experimental data of protein kinases profiling assay (<ce:cross-ref refid="appsec2" id="crosref0555">Table S2</ce:cross-ref>); Representative 1H-NMR spectra of some indolinones derivatives (<ce:cross-ref refid="appsec2" id="crosref0560">Fig. S1</ce:cross-ref>); Correlation between experimental and reported human BBB permeability of commercial drugs using the PAMPA-BBB assay (<ce:cross-ref refid="appsec2" id="crosref0565">Fig. S2</ce:cross-ref>) together with predicted BBB permeability of indolinone derivatives (<ce:cross-ref refid="appsec2" id="crosref0570">Table S3</ce:cross-ref>); Calculated physicochemical properties of some diphenylhydrazono-indolinones (<ce:cross-ref refid="appsec2" id="crosref0575">Table S4</ce:cross-ref>); ADMET Prediction for synthetized indolinones: Metabolism score and number of reactive functional groups (<ce:cross-ref refid="appsec2" id="crosref0580">Table S5</ce:cross-ref>).<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>supplementary</ce:label>
                           <ce:alt-text role="short" id="alttext0015a">supplementary</ce:alt-text>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523417305147/mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0105">Supplementary data</ce:section-title>
                  <ce:para id="p0495" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2017.06.060" id="intref0010" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2017.06.060</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0110">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zimprich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Biskup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Leitner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lichtner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Farrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lincoln</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kachergus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hulihan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Uitti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Calne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Stoessl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Pfeiffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Patenge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.C.</ce:given-name>
                                 <ce:surname>Carbajal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vieregge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Asmus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Muller-Myhsok</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Dickson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Meitinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Strom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Wszolek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Gasser</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>601</sb:first-page>
                              <sb:last-page>607</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Healy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Falchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>O'Sullivan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bonifati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Durr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bressman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Brice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Aasly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Zabetian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Goldwurm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Ferreira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tolosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Kay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Marras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Wszolek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Berciano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Schapira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lynch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.P.</ce:given-name>
                                 <ce:surname>Bhatia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Gasser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Lees</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.W.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>International</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Neurol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>583</sb:first-page>
                              <sb:last-page>590</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Gilligan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Top. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>927</sb:first-page>
                              <sb:last-page>938</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Estrada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical biology of leucine-rich repeat kinase 2 (LRRK2) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6733</sb:first-page>
                              <sb:last-page>6746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Cookson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>LRRK2 pathways leading to neurodegeneration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Neurol. Neurosci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>42</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Steger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Tonelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Trost</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vetter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wachter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lorentzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Duddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Baptista</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Fiske</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Fell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Morrow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Reith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Alessi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Elife</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of the LRRK2 gene in Parkinsonism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Neurodegener.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>47</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Berwick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Harvey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>LRRK2: an eminence grise of Wnt-mediated neurogenesis?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Cell Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>82</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Abdipranoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Stayte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vissel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>CNS Neurol. Disord. Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>187</sb:first-page>
                              <sb:last-page>210</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Lamm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ganz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Melamed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Offen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Harnessing neurogenesis for the possible treatment of Parkinson's disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comp. Neurol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>522</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2817</sb:first-page>
                              <sb:last-page>2830</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hirota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sawada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ogino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ohata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kubo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sawamoto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roles of Wnt signaling in the neurogenic niche of the adult mouse ventricular-subventricular zone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neurochem. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>222</sb:first-page>
                              <sb:last-page>230</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wetzel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Bon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Waldmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biology-oriented synthesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem. Int. Ed. Engl.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>50</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10800</sb:first-page>
                              <sb:last-page>10826</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wilk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Zimmermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kaiser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Waldmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Principles, implementation, and application of biology-oriented synthesis (BIOS)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>491</sb:first-page>
                              <sb:last-page>497</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Medvedev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Buneeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Glover</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological targets for isatin and its analogues: implications for therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biologics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>151</sb:first-page>
                              <sb:last-page>162</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kaur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Chadha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silakari</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oxindole: a chemical prism carrying plethora of therapeutic benefits</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>858</sb:first-page>
                              <sb:last-page>894</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Ikotun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.O.</ce:given-name>
                                 <ce:surname>Egharevba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Obafemi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Owoseni</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ring deactivating effect on antimicrobial activities of metal complexes of the schiff base of p-nitroaniline and isatin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>416</sb:first-page>
                              <sb:last-page>422</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Raghuvanshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microwave-assisted, solvent-free synthesis of 3’-(aryl/heteroaryl)-1-morpholinomethyl/piperidinomethylspiro[3H-indole-3,2’-thiazolidine]-2,4’(1H)-diones via 3-isatinimines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Heterocycl. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>49</sb:first-page>
                              <sb:last-page>53</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kaur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kishore</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Montmorillonite: an efficient, heterogeneous and green catalyst for organic synthesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>991</sb:first-page>
                              <sb:last-page>1015</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ottoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cruz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Alves</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficient and simple methods for the introduction of the sulfonyl, acyl and alkyl protecting groups on the nitrogen of indole and its derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13915</sb:first-page>
                              <sb:last-page>13928</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Correia Guedes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Ferreira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Rosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Coelho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bonifati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sampaio</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Park. Relat. Disord.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>237</sb:first-page>
                              <sb:last-page>242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>West</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Biskup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bugayenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Ross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16842</sb:first-page>
                              <sb:last-page>16847</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Bender</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Cuny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Sherman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Glicksman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1725</sb:first-page>
                              <sb:last-page>1736</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hassanein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Almahayni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.O.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gaballa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>El Fakih</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3 inhibitors for treating acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Lymphoma Myeloma Leuk.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>543</sb:first-page>
                              <sb:last-page>549</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Drummond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Estrada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gunzner-Toste</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Moffat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.K.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Burdick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5536</sb:first-page>
                              <sb:last-page>5545</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Di</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Kerns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.J.</ce:given-name>
                                 <ce:surname>McConnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.T.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High throughput artificial membrane permeability assay for blood-brain barrier</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>223</sb:first-page>
                              <sb:last-page>232</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Crivori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cruciani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Carrupt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Testa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Predicting blood-brain barrier permeation from three-dimensional molecular structure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2204</sb:first-page>
                              <sb:last-page>2216</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Alkass</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Salehpour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Perl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tisdale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Possnert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Druid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Frisen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Neurogenesis in the striatum of the adult human brain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>156</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1072</sb:first-page>
                              <sb:last-page>1083</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gil-Perotin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Duran-Moreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cebrian-Silla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ramirez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Garcia-Belda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Garcia-Verdugo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adult neural stem cells from the subventricular zone: a review of the neurosphere assay</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anat. Rec. Hob.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>296</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1435</sb:first-page>
                              <sb:last-page>1452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Herrera-Arozamena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Marti-Mari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Estrada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>de la Fuente Revenga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Rodriguez-Franco</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <ce:doi>10.3390/molecules21091165</ce:doi>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kriza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ignat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Stanica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Draghici</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and characterization of Cu(II), Co(II) and Ni(II) complexes with Schiff bases derived from isatin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rev. Chim.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>696</sb:first-page>
                              <sb:last-page>701</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Vine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Locke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ranson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Benkendorff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Pyne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Bremner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In vitro cytotoxicity evaluation of some substituted isatin derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>931</sb:first-page>
                              <sb:last-page>938</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.V.</ce:given-name>
                                 <ce:surname>Kouznetsov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Bello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Amado</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A simple entry to novel spiro dihydroquinoline-oxindoles using Povarov reaction between 3-N-aryliminoisatins and isoeugenol</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5855</sb:first-page>
                              <sb:last-page>5857</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dandia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shivpuri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improved synthesis of trifluoromethyl substituted 3-spiro indolines and 3-indolyimines under microwaves irradiation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Indian J. Chem. Technol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>201</sb:first-page>
                              <sb:last-page>205</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.R.</ce:given-name>
                                 <ce:surname>Mughal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.,S.</ce:given-name>
                                 <ce:surname>Samreen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Choudhary</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Schiff bases of isatin: potential anti-leishmanial agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lett. Drug Des. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>243</sb:first-page>
                              <sb:last-page>249</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Quan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Zhen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.P.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Practical synthesis, antidepressant, and anticonvulsant activity of 3-phenyliminoindolin-2-one derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>342</sb:first-page>
                              <sb:last-page>351</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Bari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Agrawal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.K.</ce:given-name>
                                 <ce:surname>Patil</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and pharmacological evaluation of some novel isatin derivatives for antimicrobial activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Sci. Islam. Repub. Iran.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>217</sb:first-page>
                              <sb:last-page>222</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Šekularac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Nikolić</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.,B.</ce:given-name>
                                 <ce:surname>Petrović</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Đurovićsaša</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Drmanić</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, antimicrobial and antioxidative activity of some new isatin derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Serb. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1347</sb:first-page>
                              <sb:last-page>1354</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>McGookin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reactive methylene groups. III. The ehrlich-sachs reaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Appl. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>1955</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>66</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Azizian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Morady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Soozangarzadeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asadi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of novel spiro-[3H-indole-3,3'-[1,2,4]triazolidine]-2-ones via azomethine imines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9721</sb:first-page>
                              <sb:last-page>9723</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.D.</ce:given-name>
                                 <ce:surname>Popp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential anticonvulsants. IX. Some isatin hydrazones and related compounds</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Heterocycl. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>1984</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1641</sb:first-page>
                              <sb:last-page>1645</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.M.S.A.</ce:given-name>
                                 <ce:surname>Al-Kahraman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yasinzai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of N-(2-thienylidene)amines, N-(2-hydroxybenzylidene)amines and 3-iminoindolin-2-ones as antileishmanial agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lett. Drug Des. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>491</sb:first-page>
                              <sb:last-page>495</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jiao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>N-Heterocyclic carbene-catalyzed homoenolate additions with N-aryl ketimines as electrophiles: efficient synthesis of spirocyclic γ-lactam oxindoles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Eur. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9198</sb:first-page>
                              <sb:last-page>9203</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bianchini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ribelles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.;T.,R.M.</ce:given-name>
                                 <ce:surname>Becerra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Menéndez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficient synthesis of 2-acylquinolines based on an aza-vinylogous Povarov reaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Chem. Front.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>412</sb:first-page>
                              <sb:last-page>422</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Siddiqui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Pandeya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and anticonvulsant and anti-inflammatory activities of new 3-aryl/alkylimino-1-methylindol-2-ones</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>272</sb:first-page>
                              <sb:last-page>274</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Corsico Coda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Desimoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gamba Invernizzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Quadrelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.;G.,T.</ce:given-name>
                                 <ce:surname>Righetti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Copper(II) in organic synthesis. VI1 reaction of the copper(II) acetate complex of 1-methylisatin-3-chlorophenylhydrazone with dimethyl acetylenedicarboxylate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>1987</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2843</sb:first-page>
                              <sb:last-page>2852</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sarel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Klug</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and properties of 2,2-diphenylindoxyl</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Isr. J. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>1964</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>143</sb:first-page>
                              <sb:last-page>150</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bureš</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Visible light photocatalytic aerobic oxygenation of indoles and pH as a chemoselective switch</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Catal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6853</sb:first-page>
                              <sb:last-page>6860</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bairoch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Boeckmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ferro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gasteiger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Swiss-Prot: juggling between evolution and stability</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Brief. Bioinform.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>55</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Higgins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Gibson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4673</sb:first-page>
                              <sb:last-page>4680</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Guex</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Peitsch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Electrophoresis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2714</sb:first-page>
                              <sb:last-page>2723</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ghose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jaeger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kowalczyk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Peterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Treasurywala</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Conformational searching methods for small molecules. I. Study of the SYBYL SEARCH method</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comp. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1050</sb:first-page>
                              <sb:last-page>1065</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gopalakrishnan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sowmiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Sheik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sekar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ramachandran plot on the web (2.0)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Protein Pept. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>669</sb:first-page>
                              <sb:last-page>671</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Eisenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Luthy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.U.</ce:given-name>
                                 <ce:surname>Bowie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>VERIFY3D: assessment of protein models with three-dimensional profiles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Methods Enzymol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>396</sb:first-page>
                              <sb:last-page>404</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Nieto-Estevez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.O.</ce:given-name>
                                 <ce:surname>Oueslati-Morales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pickel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Morales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Vicario-Abejon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Brain insulin-like growth factor-I directs the transition from stem cells to mature neurons during postnatal/adult hippocampal neurogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Stem Cells</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2194</sb:first-page>
                              <sb:last-page>2209</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>